var title_f42_4_43072="Kyphosis children PI";
var content_f42_4_43072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Kyphosis in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A normal spine (left) has a slight curve. In a child with kyphosis, the upper part of the spine curves more than normal (right), causing a rounded or hunched back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43072=[""].join("\n");
var outline_f42_4_43072=null;
var title_f42_4_43073="Ruptured spleen with arterial blush";
var content_f42_4_43073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ruptured spleen with arterial blush on contrast-enhanced computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This adolescent received a direct blow to his left upper quadrant while playing soccer. Note the extravasation of intravenous contrast from the spleen (yellow arrow) and the large amount of free fluid in the abdomen (white arrows). He recovered without operation after one transfusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Wesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43073=[""].join("\n");
var outline_f42_4_43073=null;
var title_f42_4_43074="Identification poison ivy";
var content_f42_4_43074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Identification of poison ivy, oak, and sumac",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic features useful for identifying poison ivy, poison oak, and poison sumac. Poison ivy and poison oak are often identified by three leaflets with flowering branches arising from axillary positions on a single stem. Poison sumac more often forms leaflets of five, seven, or more that angle upward toward the top of the stem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43074=[""].join("\n");
var outline_f42_4_43074=null;
var title_f42_4_43075="Classic juvenile pityriasis rubra pilaris - Back";
var content_f42_4_43075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Classic juvenile pityriasis rubra pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic pityriasiform scaling is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43075=[""].join("\n");
var outline_f42_4_43075=null;
var title_f42_4_43076="Diagnosis of acromegaly";
var content_f42_4_43076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of acromegaly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43076/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43076/contributors\">",
"     Shlomo Melmed, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43076/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43076/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43076/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43076/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/4/43076/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly results from persistent hypersecretion of growth hormone (GH). Excess GH stimulates hepatic secretion of insulin-like growth factor-I (IGF-I), which causes most of the clinical manifestations of acromegaly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical diagnosis is often delayed because of the slow progression of the signs of acromegaly over a period of many years. Growth hormone excess that occurs before fusion of the epiphyseal growth plates in a child or adolescent is called pituitary gigantism and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13464?source=see_link\">",
"     \"Pituitary gigantism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both serum GH concentrations and IGF-I concentrations are increased in virtually all patients with acromegaly. The increases in serum IGF-I are often disproportionately greater than those in GH for two reasons: GH secretion fluctuates more, and GH stimulates the secretion of IGF-I-binding protein-3 (IGFBP-3), the major IGF-I binding protein in serum.",
"   </p>",
"   <p>",
"    Once a patient is suspected to have acromegaly, the next steps are biochemical testing to confirm the clinical diagnosis and radiologic testing to determine the cause of the excess GH secretion. The cause is a somatotroph adenoma of the pituitary in over 95 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef73104 \" href=\"mobipreview.htm?36/54/37739\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sequential diagnosis approach to acromegaly will be reviewed here. Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7322?source=see_link\">",
"     \"Treatment of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DOCUMENTING EXCESS GH SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acromegaly can be confirmed by measurement of both serum GH concentration after a glucose load and GH-dependent circulating molecules, such as IGF-I and IGFBP-3 (",
"    <a class=\"graphic graphic_algorithm graphicRef71636 \" href=\"mobipreview.htm?18/3/18494\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serum IGF-I concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best",
"    <strong>",
"     single",
"    </strong>",
"    test for the diagnosis of acromegaly is measurement of serum IGF-I. Unlike growth hormone, serum IGF-I concentrations do not vary from hour to hour according to food intake, exercise or sleep, but instead reflect integrated GH secretion during the preceding day or longer. Serum IGF-I concentrations are elevated in virtually all patients with acromegaly and provide excellent discrimination from normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results must be interpreted, however, according to the patient's age. In normal subjects, serum IGF-I concentrations are highest during puberty and decline gradually thereafter. Values are significantly lower in adults over the age of 60 than in younger subjects. Thus, an apparently \"normal\" value in a patient aged 70 years may in fact be elevated.",
"   </p>",
"   <p>",
"    A further caution is that values from one laboratory may not be comparable to those from another laboratory. A major cause of this finding is a difference in the calibration standards for the assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serum GH concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum growth hormone is indicated in patients with equivocal serum IGF-I values, or in those with elevated serum IGF-I values in whom further biochemical confirmation is required. GH secretion in normal subjects is pulsatile, diurnal, and stimulated by a variety of factors, including short-term fasting, exercise, stress, and sleep; in addition, GH clearance is rapid (plasma half-life about 20 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, serum GH concentrations fluctuate widely, ranging from less than 0.5 to 1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (less than 0.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    using very sensitive assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/7\">",
"     7",
"    </a>",
"    ]) during most of the day, to 2 to 5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    before the next meal or after exercise, to as high as 20 or 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    at night or after vigorous exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/8\">",
"     8",
"    </a>",
"    ]. Serum GH concentrations also may be high in patients with uncontrolled diabetes mellitus, liver disease, and malnutrition.",
"   </p>",
"   <p>",
"    All patients with acromegaly have increased GH secretion. However, the random serum GH concentration is often in the range of 2 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    during much of the day, values that can be found in normal subjects. Unlike normal subjects, the patient's serum GH concentrations change little during the day or night, and in most patients do not change in response to stimuli such as food or exercise. Nevertheless, because of the variations in serum GH that occur in normal subjects and in patients with other disorders, a high value cannot be interpreted without knowing when the blood sample was obtained and something about the patient. To obviate these problems it is best not to obtain random measurements of serum GH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oral glucose tolerance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most specific dynamic test for establishing the diagnosis of acromegaly is an oral glucose tolerance test (OGTT). In normal subjects, serum GH concentrations fall to 1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or less within two hours after ingestion of 75 g glucose. In contrast, the post-glucose values are greater than 2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in over 85 percent of patients with acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/9\">",
"     9",
"    </a>",
"    ]. OGTT is the gold standard for determining control of GH secretion after surgical treatment, but it does not appear to be useful in assessing biochemical control in patients receiving medical therapy with somatostatin analogs. In these patients, both basal and post-glucose GH levels are highly discordant with serum IGF-1 concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an OGTT is performed, a single two-hour serum GH measurement is usually adequate. However, a more common procedure is to measure serum GH before and one and two hours after glucose administration; again, the criterion for the diagnosis is a GH concentration greater than 1",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    These results were obtained mainly with a radioimmunoassay method for the measurement of GH. If one of the newer, highly sensitive immunoradiometric or immunochemiluminescent GH assays is used, the serum GH concentration falls to less than 0.3",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    after oral glucose administration in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. Thus, the diagnosis of acromegaly can be made when the serum GH concentration remains above 0.3",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    More importantly, these more sensitive assays may give better discrimination between those with and without acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other dynamic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rarely necessary, other dynamic tests can be done. Thyrotropin-releasing hormone (TRH), in a dose of 500 mcg intravenously, raises serum GH concentrations by 50 percent or more in about one-half of patients with acromegaly, with peak values occurring at 20 to 30 minutes; serum GH does not rise in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/12\">",
"     12",
"    </a>",
"    ]. Conversely, L-dopa (500 mg orally) reduces serum GH concentrations by 50 percent or more in about one-half of patients with acromegaly, while it raises the GH concentration in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/13\">",
"     13",
"    </a>",
"    ]. TRH is currently unavailable in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serum IGFBP-3 concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because IGFBP-3 secretion is GH-dependent (as is IGF-I), serum IGFBP-3 concentrations are elevated in patients with acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/14\">",
"     14",
"    </a>",
"    ]. There is, however, considerable overlap of these values with those in normal persons, thereby limiting the utility of this measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DETERMINING THE SOURCE OF EXCESS GH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66552454\">",
"    <span class=\"h2\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once GH hypersecretion has been confirmed, the next step is magnetic resonance imaging (MRI) of the pituitary because a somatotroph adenoma of the pituitary is by far the most common cause of acromegaly (",
"    <a class=\"graphic graphic_table graphicRef73104 \" href=\"mobipreview.htm?36/54/37739\">",
"     table 1",
"    </a>",
"    ). In one report of 39 patients undergoing pituitary MRI for suspected acromegaly, a mass was identified in 27 of the 39 (69 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pituitary tumors as small as 2 mm in diameter can be detected with this technique, and the dimensions and anatomic extent of the tumor can be accurately identified (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63948 \" href=\"mobipreview.htm?13/43/14001\">",
"     image 1",
"    </a>",
"    ); computed tomography is less sensitive. In about 75 percent of patients with somatotroph adenomas, the tumor is a macroadenoma (tumor diameter 10 mm or more), and the tumor may extend to the parasellar or suprasellar region. An occasional patient has an empty sella with the tumor situated within the normal pituitary tissue lining the sella turcica.",
"   </p>",
"   <p>",
"    It is important to remember that MRI does not distinguish between functioning and nonfunctioning tumors; this distinction must be based upon biochemical studies. This is an important concern because approximately 10 to 20 percent of normal subjects have MRI or autopsy evidence of a pituitary microadenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other causes of acromegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare causes of acromegaly include pituitary somatotroph carcinoma, hypothalamic tumor secreting growth hormone-releasing hormone (GHRH), nonendocrine tumor secreting GHRH, ectopic secretion of GH by a nonendocrine tumor, and excess growth factor activity (acromegaloidism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/17\">",
"     17",
"    </a>",
"    ]. MRI of the head and pituitary should identify some of these tumors. If the MRI is normal, abdominal and chest imaging should be performed, followed by catheterization studies in an attempt to demonstrate an arteriovenous gradient of either GH or GHRH in the region of the tumor.",
"   </p>",
"   <p>",
"    Ectopic GHRH secretion accounts for only 0.5 percent of cases of acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43076/abstract/17\">",
"     17",
"    </a>",
"    ]. Serum GHRH is the only specific marker for this disorder, and concentrations are usually quite elevated; special arrangements with a reliable laboratory must be made for this assay. Pituitary MRI often reveals a normal-sized or enlarged gland, but other patients appear to have an adenoma. GHRH should not be measured routinely but should be if a clearcut pituitary adenoma is not seen on MRI or postoperatively if histologic and immunocytochemical examination of the excised pituitary tissue reveals somatotroph hyperplasia rather than a somatotroph adenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/8/40066?source=see_link\">",
"       \"Patient information: Acromegaly (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/27/43443?source=see_link\">",
"       \"Patient information: Acromegaly (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An algorithm for the diagnostic evaluation of patients suspected to have acromegaly is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef71636 \" href=\"mobipreview.htm?18/3/18494\">",
"     algorithm 1",
"    </a>",
"    ). A normal serum IGF-I concentration is strong evidence that the patient does",
"    <strong>",
"     not",
"    </strong>",
"    have acromegaly. If the serum IGF-I concentration is high (or equivocal), serum GH should be measured after oral glucose administration. It is equally acceptable to proceed immediately to MRI after obtaining an elevated level of IGF-I. If the MRI is normal, then studies to identify a GHRH- or GH-secreting tumor should be undertaken.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/1\">",
"      Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/2\">",
"      Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/3\">",
"      Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/4\">",
"      Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingm&uuml;ller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997; 46:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/5\">",
"      Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/6\">",
"      Iranmanesh A, Grisso B, Veldhuis JD. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1994; 78:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/7\">",
"      Chapman IM, Hartman ML, Straume M, et al. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994; 78:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/8\">",
"      Costa AC, Rossi A, Martinelli CE Jr, et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002; 87:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/9\">",
"      Jaffe CA, Pan W, Brown MB, et al. Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. J Clin Endocrinol Metab 2001; 86:4364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/10\">",
"      Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009; 94:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/11\">",
"      Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998; 83:3808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/12\">",
"      Irie M, Tsushima T. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab 1972; 35:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/13\">",
"      Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/14\">",
"      Grinspoon S, Clemmons D, Swearingen B, Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995; 80:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/15\">",
"      Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/16\">",
"      Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43076/abstract/17\">",
"      Garby L, Caron P, Claustrat F, et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab 2012; 97:2093.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6635 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43076=[""].join("\n");
var outline_f42_4_43076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DOCUMENTING EXCESS GH SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serum IGF-I concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serum GH concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oral glucose tolerance test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other dynamic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serum IGFBP-3 concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DETERMINING THE SOURCE OF EXCESS GH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66552454\">",
"      MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other causes of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6635|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?18/3/18494\" title=\"algorithm 1\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6635|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/43/14001\" title=\"diagnostic image 1\">",
"      Invasive GH secreting tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/54/37739\" title=\"table 1\">",
"      Causes of acromegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/8/40066?source=related_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13464?source=related_link\">",
"      Pituitary gigantism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7322?source=related_link\">",
"      Treatment of acromegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_4_43077="Propranolol: Patient drug information";
var content_f42_4_43077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Propranolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     see \"Propranolol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=see_link\">",
"     see \"Propranolol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Inderal&reg; LA;",
"     </li>",
"     <li>",
"      InnoPran XL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Propranolol&reg;;",
"     </li>",
"     <li>",
"      Dom-Propranolol;",
"     </li>",
"     <li>",
"      Inderal&reg;;",
"     </li>",
"     <li>",
"      Inderal&reg; LA;",
"     </li>",
"     <li>",
"      Novo-Pranol;",
"     </li>",
"     <li>",
"      Nu-Propranolol;",
"     </li>",
"     <li>",
"      PMS-Propranolol;",
"     </li>",
"     <li>",
"      Propranolol Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Teva-Propranolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop tremor (essential).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart attack to stop future heart attacks and lengthen life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop performance anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop rebleeding from esophageal varices in cirrhosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bold or forceful actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702812",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to propranolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703313",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, Raynaud's disease, very bad lung disease, very weak heart, slow heartbeat without a working pacemaker, or water in the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 12 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take capsule with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix liquid with a drink or soft food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11004 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43077=[""].join("\n");
var outline_f42_4_43077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214907\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214908\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011677\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011679\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011678\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011683\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011684\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011686\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011681\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011682\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011687\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011688\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=related_link\">",
"      Propranolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=related_link\">",
"      Propranolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_4_43078="Glycopyrrolate (glycopyrronium): Pediatric drug information";
var content_f42_4_43078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glycopyrrolate (glycopyrronium): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"    see \"Glycopyrrolate (glycopyrronium): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/0/44036?source=see_link\">",
"    see \"Glycopyrrolate (glycopyrronium): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cuvposa&trade;;",
"     </li>",
"     <li>",
"      Robinul&reg;;",
"     </li>",
"     <li>",
"      Robinul&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2969522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Glycopyrrolate Injection, USP;",
"     </li>",
"     <li>",
"      Seebri&reg; Breezhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12674633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Limited data available: Endotracheal intubation, nonemergent: 4-10 mcg/kg as a single dose (acceptable, but not preferred vagolytic) (Kumar, 2010). A small study of 20 neonates used 3-5 mcg/kg as a single dose prior to intubation (Pokela, 1994)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"      see \"Glycopyrrolate (glycopyrronium): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chronic drooling:",
"     </b>",
"     Oral solution (Cuvposa&trade;): Children and Adolescents 3-16 years: 20 mcg/kg/dose 3 times daily, titrate in increments of 20 mcg/kg/dose every 5-7 days as tolerated to response up to a maximum dose of 100 mcg/kg/dose 3 times daily; not to exceed 1500-3000 mcg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Control of secretions (chronic):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 40-100 mcg/kg/dose 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 4-10 mcg/kg/dose every 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reduction of secretions (preoperative):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;2 years: 4-9 mcg/kg/dose 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2 years: 4 mcg/kg/dose 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reversal of bradycardia, vagal reflexes (intraoperative):",
"     </b>",
"     I.V.: 4 mcg/kg/dose (maximum dose: 100 mcg/dose) at 2-3 minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reversal of muscarinic effects of cholinergic agents:",
"     </b>",
"     I.V.: 0.2",
"     <b>",
"      mg",
"     </b>",
"     for each 1 mg of neostigmine or 5 mg of pyridostigmine administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reduction of secretions (preoperative):",
"     </b>",
"     I.M.: 4 mcg/kg 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reversal of bradycardia, vagal reflexes (intraoperative):",
"     </b>",
"     I.V.: 0.1",
"     <b>",
"      mg",
"     </b>",
"     repeated as needed at 2-3 minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reversal of neuromuscular blockade:",
"     </b>",
"     I.V.: 0.2",
"     <b>",
"      mg",
"     </b>",
"     for each 1 mg of neostigmine or 5 mg of pyridostigmine administered or 5-15 mcg/kg glycopyrrolate with 25-70 mcg/kg of neostigmine or 0.1-0.3 mg/kg of pyridostigmine (agents usually administered simultaneously, but glycopyrrolate may be administered first if bradycardia is present)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Elimination is severely impaired in renal failure; dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.2 mg/mL (1 mL, 2 mL, 5 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robinul&reg;: 0.2 mg/mL (1 mL, 2 mL, 5 mL, 20 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cuvposa&trade;: 1 mg/5 mL (473 mL) [contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robinul&reg;: 1 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robinul&reg; Forte: 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes: Oral solution; Inhaler (Canadian availability; not available in U.S.)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Tablets: Administer without regard to meals; Oral solution: Administer on an empty stomach, 1 hour before or 2 hours after meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May be administered undiluted I.M. or direct I.V. at a maximum rate of 20 mcg/minute. May be diluted to a concentration of 2 mcg/mL (maximum concentration: 200 mcg/mL); infuse over 15-20 minutes; pH: 2.3.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F176949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, R;",
"     <b>",
"      incompatible",
"     </b>",
"     in LR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Palonosetron, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, buprenorphine with haloperidol, butorphanol, chlorpromazine, cimetidine, codeine, diphenhydramine, droperidol, droperidol and fentanyl, hydromorphone, hydroxyzine, lidocaine, meperidine, midazolam, morphine, nalbuphine, neostigmine, ondansetron, oxymorphone, palonosetron, physostigmine, prochlorperazine edisylate, promethazine, pyridostigmine, ranitidine, scopolamine, trimethobenzamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Chloramphenicol, dexamethasone sodium phosphate, diazepam, dimenhydrinate, methohexital, pentazocine, pentobarbital, secobarbital, sodium bicarbonate, thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature 20&deg;C to 25&ordm;C (68&deg;F to 77&ordm;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral: Unstable at pH &gt;6; compatible in the same syringe with atropine, codeine, diphenhydramine, droperidol, fentanyl, hydromorphone, hydroxyzine, lidocaine, meperidine, promethazine, morphine, neostigmine, procaine, prochlorperazine, pyridostigmine, scopolamine, and trimethobenzamide",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Adjunct in treatment of peptic ulcer disease (FDA approved in adults).",
"     <b>",
"      Note:",
"     </b>",
"     Indication listed in product labeling but currently has no place in management of peptic ulcer disease. Has also been used for control of upper airway secretions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution (Cuvposa&trade;): Treatment of severe chronic drooling in association with neurologic conditions (eg, cerebral palsy) (FDA approved in ages 3-16 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Used preoperatively to inhibit salivation and excessive secretions of the respiratory tract, reduce volume and acidity of gastric secretions, and blockade of cardiac vagal inhibitory reflexes during induction of anesthesia and intubation; used intraoperatively to counteract surgically, drug-induced, or vagal mediated bradyarrhythmias; reversal of the muscarinic effects of cholinergic agents, such as neostigmine and pyridostigmine, during reversal of neuromuscular blockade (FDA approved in ages &ge;1 month and adults); adjunct in treatment of peptic ulcer (FDA approved in adults).",
"     <b>",
"      Note:",
"     </b>",
"     Indication of peptic ulcer listed in product labeling but currently has no place in management of peptic ulcer disease.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Robinul [U.S. and multiple international markets] may be confused with Reminyl brand name for galantamine [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F176948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, cardiac arrest, flushing, heart block, hyper-/hypotension, malignant hyperthermia, pallor, palpitation, QT",
"     <sub>",
"      c",
"     </sub>",
"     -interval prolongation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressiveness, agitation, confusion, crying (abnormal), dizziness, drowsiness, excitement, headache, insomnia, irritability, mood changes, pain , restlessness , nervousness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry skin, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, lactation suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, abdominal pain, constipation, flatulence, retching, bloated feeling, intestinal obstruction, loss of taste, nausea, pseudo-obstructio, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitancy, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (edema, erythema, pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cycloplegia, mydriasis, nystagmus, ocular tension increased, photophobia, sensitivity to light increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial secretion (thickening), nasal congestion, nasal dryness, pneumonia, respiratory depression, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, diaphoresis decreased, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      As reported with Seebri&reg; Breezhaler&reg; (Canadian availability; not available in U.S.)",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Gastrointestinal: Dyspepsia, gastroenteritis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Genitourinary: Dysuria, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Respiratory: Nasopharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Rare but important or life-threatening: Cough, cystitis, dental caries, diabetes mellitus, epistaxis, fatigue, hypoesthesia, palpitations, rash, throat irritation, urinary retention, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glycopyrrolate or any component; medical conditions that preclude use of anticholinergic medication; narrow-angle glaucoma; acute hemorrhage; tachycardia; severe ulcerative colitis; obstructive uropathy; paralytic ileus; myasthenia gravis; intestinal atony; obstructive disease of GI tract (pyloric stenosis); intestinal atony in the elderly or debilitated patient, toxic megacolon complicating ulcerative colitis; oral solution (Cuvposa&trade;): Concomitant use of solid oral dosage forms of potassium chloride",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; if function severely impaired, dosage adjustment should be considered. Use with caution in patients with autonomic neuropathy, fever, hyperthyroidism, hepatic or renal disease, hypertension, coronary artery disease, CHF, tachyarrhythmias, reflux esophagitis, or hiatal hernia with reflux. Use with caution in patients with diarrhea; diarrhea may be a sign of incomplete intestinal obstruction, especially in patients with an ileostomy or colostomy. Discontinue treatment if this occurs. Use with caution in patients with ulcerative colitis as large doses suppress intestinal motility; may precipitate/exacerbate an ileus or toxic megacolon.  Use with caution in individuals demonstrating decreased pigmentation (skin and iris coloration, dark vs light) since there has been some evidence that these individuals have an enhanced sensitivity to the anticholinergic response. In children treated with Cuvposa&trade;, the following adverse reactions were reported with incidences &gt;30%:  Flushing, constipation, vomiting, xerostomia, and nasal congestion.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, patients with Down syndrome, and children with spastic paralysis or brain damage may be hypersensitive to antimuscarinic effects. Paradoxical excitation may occur in infants and young children. May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May decrease sweating leading to heat prostration (eg, fever  or heat stroke) in the presence of increased environmental temperature; use caution in hot weather and/or exercise. Slowing of GI muscular action can occur resulting in constipation or intestinal pseudo-obstruction. Constipation is a common dose-limiting adverse event; usually reported 4-5 days after therapy initiation or dose increases. Intestinal pseudo-obstruction can result in abdominal distention, pain, nausea, or vomiting.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use parenteral injection containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution (Cuvposa&trade;) contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use oral solutions containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: May enhance the anticholinergic effect of Glycopyrrolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atenolol: Glycopyrrolate may increase the serum concentration of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Glycopyrrolate may increase the serum concentration of Digoxin. This effect is specific to digoxin administered as slow dissolution oral tablets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Glycopyrrolate may decrease the serum concentration of Haloperidol.  Management: Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required.  When possible, consider avoiding concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Glycopyrrolate may decrease the serum concentration of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Glycopyrrolate may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Glycopyrrolate may enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride.  Management: Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.  Consider using a non-solid oral dosage form or another alternative therapy as appropriate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13228331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High-fat meals decrease absorption of oral solution by 74% compared to fasting conditions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (injection) / C (oral solution) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Small amounts of glycopyrrolate cross the human placenta.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate; anticholinergic effects; bowel sounds; bowel movements; effects on drooling",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the muscarinic action of acetylcholine at postganglionic parasympathetic neuroeffector sites in smooth muscle, secretory glands, and CNS",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral: ~1 hour; I.M.: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Vagal effect: 2-3 hours; inhibition of salivation: Up to 7 hours; anticholinergic: Oral: 8-12 hours; Parenteral: 7 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral tablets: Poor (~3%); variable and erratic; Oral solution: 23% lower compared to tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients (1-14 years): Mean range: 1.3-1.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.2-0.64 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 22-130 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 19-99 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: ~60-75 minutes; Oral solution: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (as unchanged drug, I.M.: 80%, I.V.: 85%); bile (as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients (1-14 years): Mean range: 1-1.4 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Mean range: 0.4-0.68 L/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/0/44036?source=see_link\">",
"      see \"Glycopyrrolate (glycopyrronium): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take before meals. Void before taking medication. May cause dizziness, blurred vision, dry mouth, photosensitivity, decreased ability to sweat, or impotence (temporary). Report excessive and persistent anticholinergic effects (blurred vision, headache, flushing, tachycardia, nervousness, constipation, dizziness, insomnia, mental confusion or excitement, dry mouth, altered taste perception, dysphagia, palpitations, bradycardia, urinary hesitancy or retention, impotence, decreased sweating).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F12747186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 0.5 mg/mL oral suspension may be made with 1 mg tablets and  a 1:1 mixture of Ora-Plus&reg; and either Ora-Sweet&reg; or Ora-Sweet&reg; SF. Crush thirty 1 mg tablets in a mortar and reduce to a fine powder. Prepare diluent by mixing 30 mL of Ora-Plus&reg; with 30 mL of either Ora-Sweet&reg; or Ora-Sweet&reg; SF and stir vigorously.  Add 30 mL of diluent (via geometric dilution) to powder until smooth suspension is obtained. Transfer suspension to 60 mL amber bottle. Rinse contents of mortar into bottle with sufficient quantity of remaining diluent to obtain 60 mL (final volume). Label &ldquo;shake well&rdquo;. Stable at room temperature for 90 days. Due to bitter aftertaste, chocolate syrup may be administered prior to or mixed (1:1 v/v) with suspension immediately before administration (Cober, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.5 mg/mL oral solution can be made from tablets. Crush fifty 1 mg tablets in a mortar and reduce to a fine powder. Add enough distilled water to make about 90 mL, mix well. Transfer to a bottle, rinse mortar with water, and add a quantity of water sufficient to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable at room temperature for 25 days (Gupta, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.1 mg/mL oral solution may be made using glycopyrrolate 0.2 mg/mL injection without preservatives. Withdraw 50 mL from vials with a needle and syringe, add to 50 mL of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; in a bottle. Label &ldquo;shake well&rdquo;, &ldquo;protect from light,&rdquo; and &ldquo;refrigerate&rdquo;. Stable refrigerated for 35 days (Landry, 2005).",
"    </p>",
"    <div class=\"reference\">",
"     Cober MP, Johnson CE, Sudekum D, et al, &ldquo;Stability of Extemporaneously Prepared Glycopyrrolate Oral Suspensions,&rdquo;",
"     <i>",
"      Am J Health Syst Phar",
"     </i>",
"     ,. 2011, 68(9):843-5.",
"     <span class=\"pubmed-id\">",
"      21515869",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Gupta VD, &ldquo;Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets,&rdquo;",
"     <i>",
"      IJPC",
"     </i>",
"     2001, 5(6):480-1.",
"    </div>",
"    <div class=\"reference\">",
"     Landry C, &ldquo;Stability and Subjective Taste Acceptability of Four Glycopyrrolate Solutions for Oral Administration,&rdquo;",
"     <i>",
"      IJPC",
"     </i>",
"     , 2005, 9(5):396-98.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/4/43078/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hume-Smith H, McCormack J, Montgomery C, et al, \"The Effect of Age on the Dose of Remifentanil for Tracheal Intubation in Infants and Children,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2010, 20(1):19-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/4/43078/abstract-text/19968808/pubmed\" id=\"19968808\" target=\"_blank\">",
"        19968808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar P, Denson SE, Mancuso TJ, et al, \"Premedication for Nonemergency Endotracheal Intubation in the Neonate,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(3):608-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/4/43078/abstract-text/20176672/pubmed\" id=\"20176672\" target=\"_blank\">",
"        20176672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nilsson E, Ingvarsson L, and Isern E, \"Treacher Collins Syndrome With Choanal Atresia: One Way to Handle the Airway,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2004, 14(8):700-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/4/43078/abstract-text/15283837/pubmed\" id=\"15283837\" target=\"_blank\">",
"        15283837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pokela ML and Koivisto M, \"Physiological Changes, Plasma Beta-Endorphin and Cortisol Responses to Tracheal Intubation in Neonates,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 1994, 83(2):151-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/4/43078/abstract-text/8193492/pubmed\" id=\"8193492\" target=\"_blank\">",
"        8193492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13338 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43078=[""].join("\n");
var outline_f42_4_43078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176915\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2969522\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059006\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12674633\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058999\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176894\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176879\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059010\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176949\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059002\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059009\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913945\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176948\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059014\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058998\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058997\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299415\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176888\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13228331\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176890\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744542\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059005\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058996\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059012\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059013\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059004\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12747186\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/0/44036?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_4_43079="Atrial tachycardia ECG 1";
var content_f42_4_43079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Atrial tachycardia ECG 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 445px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiographic tracing showing a narrow complex tachycardia with uniform P waves consistent with atrial tachycardia originating from the tricuspid annulus. Prior to the final QRS complex there is spontaneous return to normal sinus rhythm with P wave of a different morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Kistler, MBBS, FRACP, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43079=[""].join("\n");
var outline_f42_4_43079=null;
var title_f42_4_43080="Blood pressure measurement in the diagnosis and management of hypertension in adults";
var content_f42_4_43080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blood pressure measurement in the diagnosis and management of hypertension in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     George Thomas, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     Marc A Pohl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43080/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/4/43080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correct measurement and interpretation of the blood pressure (BP) is essential in the diagnosis and management of hypertension. It is essential that BP machines are properly calibrated, appropriate cuff sizes are selected, and, when BP is measured in an office-based setting, personnel are properly trained and the patient is positioned correctly.",
"   </p>",
"   <p>",
"    BP measurement in the diagnosis and management of hypertension, including the technique required for office-based measurements, will be reviewed here. Detailed descriptions of ambulatory and home-based BP monitoring are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of hypertension in adults and discussions pertaining to patient selection for antihypertensive therapy, choice of antihypertensive therapy, and management of older adults with isolated systolic hypertension can be found in other topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10945837\">",
"    <span class=\"h1\">",
"     METHODS FOR THE DIAGNOSIS OF HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension can be diagnosed using one of the following three acceptable measurement strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ambulatory blood pressure monitoring (ABPM)",
"     </li>",
"     <li>",
"      Home blood pressure monitoring",
"     </li>",
"     <li>",
"      Office-based blood pressure measurements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to the British National Institute for health and Clinical Excellence (NICE) guidelines published in 2011, ambulatory blood pressure (BP) should be used to confirm the diagnosis of hypertension if office-based BP is elevated; home BP monitoring should be used to confirm the diagnosis in patients who cannot obtain or tolerate ambulatory monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/1\">",
"     1",
"    </a>",
"    ]. According to the American Heart Association (AHA) guidelines published in 2005, office-based BP can be used to diagnose hypertension. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10945858\">",
"    <span class=\"h1\">",
"     AMBULATORY AND HOME BLOOD PRESSURE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory blood pressure monitoring (ABPM) is determined using a device (worn by the patient) that takes blood pressure (BP) measurements over a 24- to 48-hour period, usually every 15 to 20 minutes during the daytime and every 30 to 60 minutes during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/2\">",
"     2",
"    </a>",
"    ]. These blood pressures are recorded on the device, and the average day (diurnal) or night (nocturnal) blood pressures are determined from the data by a computer. The percentage of BP readings exceeding the upper limit of normal can also be calculated. When ABPM is used, hypertension is defined as a BP greater than or equal to",
"    <span class=\"nowrap\">",
"     135/85",
"    </span>",
"    mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H4#H4\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Definition of hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABPM has been considered to be the reference standard for the diagnosis of hypertension and is a better predictor of future cardiovascular events as compared with conventional office-based BP measurements. A patient with elevated office-based BP but normal 24-hour ambulatory BP is considered to have office hypertension or \"white coat\" hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H11#H11\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'White coat hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABPM is not available in most clinicians' offices. This is due to a combination of factors, including lack of knowledge regarding its utility, its expense, and minimal reimbursement by third-party payers. In addition, ABPM is a one-time (24- to 48-hour snapshot) assessment, while BP is dynamic and can vary considerably over time.",
"   </p>",
"   <p>",
"    Compared with ABPM, the sensitivity and specificity of office-based BP measurements are poor. This was shown in a systematic review of 20 studies including 5863 patients that compared ABPM with office-based and home BP monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/3\">",
"     3",
"    </a>",
"    ]. When compared with a mean 24-hour BP of",
"    <span class=\"nowrap\">",
"     135/85",
"    </span>",
"    mmHg or greater, the average sensitivity and specificity of an office-based BP of",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg or greater were both 75 percent. The positive predictive value for an elevated office-based measurement was poor. If, for example, the prevalence of hypertension in the population was 30 percent, the probability that a patient whose office-based BP was",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg or greater would have hypertension confirmed by ABPM was 56 percent. In addition to problems with accuracy, conventional office-based measurement of BP may be a less cost-effective way to diagnose hypertension than ABPM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10945925\">",
"    <span class=\"h2\">",
"     Home blood pressure monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the cost and limited availability of ambulatory monitoring, increasing attention is being given to home monitoring with inexpensive (40 to 60 US dollars) semi-automatic devices. If the BP is taken at home to establish the diagnosis of hypertension or to assess BP control, the optimal schedule is unclear. Increasing evidence suggests that at least 12 to 14 measurements should be obtained, with both morning and evening measurements taken, over a period of one week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/2,5-12\">",
"     2,5-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such self-recorded casual BP measurements taken at home or work correlate more closely with the results of 24-hour or daytime ambulatory monitoring than with office-based measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/2,6,13,14\">",
"     2,6,13,14",
"    </a>",
"    ]. Thus, when home BP monitoring is used, hypertension is defined as a BP greater than or equal to",
"    <span class=\"nowrap\">",
"     135/85",
"    </span>",
"    mmHg, identical to the definition used for ABPM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H16#H16\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Home BP measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6381476\">",
"    <span class=\"h3\">",
"     Cuff inflation hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cuff inflation hypertension was first reported in a study examining patients with resistant hypertension. During cuff inflation, there was an average increase of 5 &plusmn; 2.9 mmHg in intra-arterial systolic BP and 4.7 &plusmn; 2.9 mmHg in intra-arterial diastolic BP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/15\">",
"     15",
"    </a>",
"    ]. Some BP monitors designed for home use, particularly ones that are less expensive, require the patient to manually inflate the cuff. If the cuff is manually inflated, the muscular activity used to inflate the cuff can acutely raise the BP by as much as",
"    <span class=\"nowrap\">",
"     12/9",
"    </span>",
"    mmHg, an effect that dissipates within 5 to 20 seconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, inflating the cuff to at least 30 mmHg above systolic and then allowing the sphygmomanometer to fall no more than 2 to 3 mmHg per heartbeat is desirable both for accurate measurement and to permit this exertional effect to disappear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10945945\">",
"    <span class=\"h1\">",
"     OFFICE-BASED BLOOD PRESSURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advantages of ambulatory blood pressure monitoring (ABPM), office-based blood pressure (BP) measurement will likely continue to be the primary technique for both the diagnosis and management of hypertension in the United States and elsewhere, largely due to the lack of payment for ABPM or home BP monitors by most third-party payers and the unavailability of ABPM or home BP monitors in some areas. In addition, the randomized trials upon which hypertension treatment recommendations are based employed office-based BP measurements, not ABPM.",
"   </p>",
"   <p>",
"    The remainder of this section will review the recommendations that have been made to achieve maximum accuracy in office-based BP measurement (",
"    <a class=\"graphic graphic_table graphicRef65136 \" href=\"mobipreview.htm?43/32/44556\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, many clinicians",
"    <strong>",
"     do not follow",
"    </strong>",
"    one or more of these recommendations, leading to potential errors in diagnosis and management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proper measurement of office-based BP requires attention to all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Time of measurement",
"     </li>",
"     <li>",
"      Type of measurement device",
"     </li>",
"     <li>",
"      Cuff size",
"     </li>",
"     <li>",
"      Patient position",
"     </li>",
"     <li>",
"      Cuff placement",
"     </li>",
"     <li>",
"      Technique of measurement",
"     </li>",
"     <li>",
"      Number of measurements",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Time of measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;BP is variable throughout the course of the day, as shown clearly by ABPM. Daytime BP, which is when patients are evaluated in the office, can change from hour to hour and is affected by mental and physical activity, stress, and when antihypertensive medications were taken. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For office monitoring of antihypertensive therapy, the BP should optimally be measured at about the same time of day and before medications are taken to estimate the trough or nadir effect. If the BP is taken soon after drug ingestion, the BP may be normal or even below normal and then will gradually increase to potentially hypertensive levels until the next dose is taken.",
"   </p>",
"   <p>",
"    Extraneous variables that can influence the BP should be avoided in the 30 minutes prior to evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/20\">",
"     20",
"    </a>",
"    ]. These include food intake, strenuous exercise (which can lower the BP), smoking, and the ingestion of caffeine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking transiently raises the BP; thus, the office BP may",
"      <strong>",
"       underestimate",
"      </strong>",
"      the usual BP in a heavy smoker who has not smoked for more than 30 minutes before the measurement is made. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3395?source=see_link\">",
"       \"Smoking and hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Caffeine intake can raise the BP acutely, primarily in non-habitual coffee drinkers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38375?source=see_link\">",
"       \"Cardiovascular effects of caffeine\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Taking the BP in a cool room (12&ordm;C or 54&ordm;F) or while the patient is talking can raise the measured value by as much as 8 to 15 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type of measurement device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both mercury and aneroid sphygmomanometers are less widely used, the former because of mercury toxicity, the latter because of frequent inaccuracies. Thus, automated oscillometric BP (AOBP) measuring devices are increasingly being used in medical offices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/18\">",
"     18",
"    </a>",
"    ] and are also used for home monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2310063\">",
"    <span class=\"h3\">",
"     Automated oscillometric BP measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;BP readings are typically lower with AOBP than with the auscultatory method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/22\">",
"     22",
"    </a>",
"    ]. The disadvantages are that the oscillometric method has somewhat greater inherent error, and epidemiologic data are based upon auscultatory methods. However, advantages are that observer error and training are minimal. Proper timing, patient positioning, cuff size, and placement are still necessary, as is evaluation of machine accuracy at periodic intervals. BP monitors that have been validated by the Association for the Advancement of Medical Instrumentation (AAMI) or British Hypertension Society (BHS) protocols should be used. Useful information about the various AOBP devices that are currently marketed can be found",
"    <a class=\"external\" href=\"file://www.dableducational.org/\">",
"     here",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Fully automated oscillometric devices take multiple consecutive BP readings in the office with the patient sitting and resting alone. Compared with conventional office measurements, a decreased white coat response with AOBP is usually observed. The currently available AOBP devices differ in the number of readings taken and the number of minutes before the first BP measurement is recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/18,23\">",
"     18,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial of 555 hypertensive patients, office readings obtained from AOBP were compared with conventional auscultatory office measurements using daytime ABPM as the gold standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/24\">",
"     24",
"    </a>",
"    ]. Before randomization, mean BP was similar in both groups",
"    <span class=\"nowrap\">",
"     (150/81",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     150/82",
"    </span>",
"    mmHg). After enrollment and randomization, the measured BP was significantly lower using the automated device",
"    <span class=\"nowrap\">",
"     (136/78",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     141/80",
"    </span>",
"    mmHg), although the mean daytime ABPM was not different between the groups",
"    <span class=\"nowrap\">",
"     (133/74",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     135/76",
"    </span>",
"    mmHg). In addition, AOBP readings were significantly closer than conventional auscultatory readings to daytime ABPM. Thus, using ABPM as the gold standard, office BP measurement with an automated device is superior to the conventional auscultatory method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cuff size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a proper-sized cuff is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/25\">",
"     25",
"    </a>",
"    ]. If too small a cuff is used, the pressure generated by inflating the cuff may not be fully transmitted to the brachial artery; in this setting, the pressure in the cuff may be considerably higher than the intra-arterial pressure, which can lead to overestimation of the systolic pressure by as much as 10 to 50 mmHg in obese patients.",
"   </p>",
"   <p>",
"    The length of the BP cuff bladder should be 80 percent, and the width at least 40 percent (and some use 46 percent), of the circumference of the upper arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21,26\">",
"     21,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the American Heart Association regarding the appropriate cuff size for a designated arm circumference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arm circumference 22 to 26 cm, \"small adult\" cuff, 12 x 22 cm",
"     </li>",
"     <li>",
"      Arm circumference 27 to 34 cm, \"adult\" cuff, 16 x 30 cm",
"     </li>",
"     <li>",
"      Arm circumference 35 to 44 cm, \"large adult\" cuff, 16 x 36 cm",
"     </li>",
"     <li>",
"      Arm circumference 45 to 52 cm, \"adult thigh\" cuff, 16 x 42 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pseudohypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another setting in which compression of the brachial artery may require a cuff pressure greater than systolic is in patients with stiff vessels due to marked arterial calcification. This phenomenon, called pseudohypertension, is characterized by systolic and diastolic pressures estimated from the sphygmomanometer that are 10 mmHg or more above the directly measured intra-arterial or oscillometric pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=see_link&amp;anchor=H20#H20\">",
"     \"Definition, risk factors, and evaluation of resistant hypertension\", section on 'Cuff inflation hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patient position",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BP should be taken with the patient in a seated position with the back supported and legs uncrossed. The diastolic pressure may be higher by 6 mmHg if the back is unsupported, and the systolic pressure may be raised by 2 to 8 mmHg if the legs are crossed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supine values tend to be slightly different, with the systolic pressure higher by two to three mmHg and the diastolic pressure lower by a similar degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/28\">",
"     28",
"    </a>",
"    ]. Supine and standing measurements should always be taken in the elderly and diabetics to detect postural hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The arm should be supported at the level of the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/25\">",
"     25",
"    </a>",
"    ]. If the arm is allowed to hang down when the patient is sitting or standing, the measured BP will be elevated by 10 to 12 mmHg due to the added hydrostatic pressure induced by gravity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/30\">",
"     30",
"    </a>",
"    ]. The patient should sit quietly for five minutes before the BP is measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/25\">",
"     25",
"    </a>",
"    ]. Bladder distension, talking, and background noise can all affect the measured BP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even under optimal conditions, many patients are apprehensive when seeing the clinician, resulting in an acute rise in BP. Twenty to 30 percent of patients with hypertension in the clinician's office are normotensive outside of the office [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/31\">",
"     31",
"    </a>",
"    ]. This phenomenon, called \"white coat\" or isolated office hypertension, should be suspected in any patient with marked hypertension in the absence of end-organ damage or with normal ambulatory blood pressures taken at work or at home. The presence of white coat hypertension can be confirmed by 24-hour ABPM or self-recorded readings at home. This white coat effect can usually be minimized by having a nurse measure the BP (",
"    <a class=\"graphic graphic_figure graphicRef73781 \" href=\"mobipreview.htm?24/2/24621\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/32\">",
"     32",
"    </a>",
"    ] and by using automated BP devices which record multiple readings with the patient alone in the examination room. This white-coat effect can persist for years (",
"    <a class=\"graphic graphic_figure graphicRef78976 \" href=\"mobipreview.htm?28/49/29469\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cuff placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BP cuff should be placed with the bladder midline over the brachial artery pulsation, with the arm without restrictive clothing (the patient's sleeve should not be rolled up as this may act as a tourniquet) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21\">",
"     21",
"    </a>",
"    ]. Although BP readings are similar with the cuff placed over a bare arm and a sleeved arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/33\">",
"     33",
"    </a>",
"    ], it should ideally be taken over the bare arm. Taking the BP over thick clothing such as a sweater should be avoided. With auscultatory readings, the lower end of the BP cuff should be two to three centimeters above the antecubital fossa to minimize artifactual noise related to the stethoscope touching the cuff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Technique of measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cuff should be inflated to a pressure approximately 30 mmHg greater than systolic, as estimated from the disappearance of the pulse in the brachial artery by palpation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/25\">",
"     25",
"    </a>",
"    ]. Initial estimation of the systolic pressure by palpation avoids potential problems with an",
"    <strong>",
"     auscultatory gap",
"    </strong>",
"    , wherein the Korotkoff sounds transiently disappear as the cuff is deflated. As an example, the Korotkoff sounds in a patient with a systolic pressure of 180 mmHg may be first heard at 180 mmHg, disappear at 165 mmHg, and then be reheard at 140 mmHg. If the cuff is only inflated to a pressure of 160 mmHg, no sounds will be heard until 140 mmHg; as a result, the latter value will be mistakenly considered to be the systolic pressure. The auscultatory gap is associated with increased arterial stiffness and carotid atherosclerosis; it may therefore identify patients at increased risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the cuff is adequately placed and inflated, the following steps should be followed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neither the patient nor the observer should talk during the measurement.",
"     </li>",
"     <li>",
"      The BP should be taken with the patient's arm supported at the level of the heart.",
"     </li>",
"     <li>",
"      With the auscultatory method, the stethoscope should be placed lightly over the brachial artery since the use of excessive pressure can increase turbulence and delay the disappearance of sound. The net effect is that the diastolic pressure reading may be artifactually reduced by up to 10 to 15 mmHg.",
"     </li>",
"     <li>",
"      The cuff should be deflated slowly at a rate of 2 to 3 mmHg per heartbeat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/35\">",
"       35",
"      </a>",
"      ]. The systolic pressure is equal to the pressure at which the brachial pulse can first be palpated as blood flow is restored through the previously compressed vessel; the systolic pressure is also equal to the pressure at which the pulse is first heard by auscultation (Korotkoff phase I).",
"     </li>",
"     <li>",
"      As the cuff is deflated below the systolic pressure, the pulse continues to be heard until there is abrupt muffling (phase IV) and, approximately 8 to 10 mmHg later, disappearance of sound (phase V) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/36\">",
"       36",
"      </a>",
"      ]. The diastolic pressure is generally equal to",
"      <strong>",
"       phase V",
"      </strong>",
"      , although the point of muffling should be used in those patients in whom there is more than a 10 mmHg difference between phases IV and V [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/26,37\">",
"       26,37",
"      </a>",
"      ]. This can occur in children and in high-output states such as thyrotoxicosis, anemia, and aortic regurgitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The BP should be measured initially in",
"    <strong>",
"     both arms",
"    </strong>",
"    , preferably simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/38\">",
"     38",
"    </a>",
"    ]. One logical way to obtain simultaneous readings is to have the patient bring their home BP device and to use it on one arm while the pressure is taken by the clinician on the other arm with the office device. If there is a large disparity due to a unilateral arterial lesion (usually a subclavian stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/39\">",
"     39",
"    </a>",
"    ]), the arm with higher pressure should be used.",
"   </p>",
"   <p>",
"    A disparity in BP between the arms predicts not only the presence of subclavian stenosis but also a higher risk of cardiovascular disease. In a meta-analysis that included 20 studies, patients who had a BP disparity of 10 mmHg or more between the arms were significantly more likely to have peripheral arterial disease (42 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/40\">",
"     40",
"    </a>",
"    ]. A disparity of 15 mmHg or more was significantly associated with a higher prevalence of cerebrovascular disease (11 versus 4 percent) and a significantly greater relative risk of cardiovascular death (relative risk 1.63, 95% CI 1.10-2.41).",
"   </p>",
"   <p>",
"    If automated devices are not being used, the BP should be taken at least twice during each office visit, with the measurements separated by one to two minutes to allow the release of trapped blood. If the second value is more than 5 mmHg different from the first, continued measurements should be made until a stable value is attained. The recorded value on the patient's chart should be the average of the last two measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10946091\">",
"    <span class=\"h2\">",
"     Need for multiple measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of end-organ damage, the diagnosis of hypertension should not be made until the BP has been measured on at least",
"    <strong>",
"     three visits",
"    </strong>",
"    , spaced over a period of one week or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequential studies have shown that the BP drops by an average of 10 to 15 mmHg between the first and third visits in newly diagnosed patients, with a stable value not being achieved in some patients until more than six visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, many patients considered to be hypertensive at the initial visit are in fact normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, multiple measurements are necessary when monitoring patients who are already on treatment for hypertension. A study of 444 men with long-standing, poorly controlled hypertension found that a single clinic or home systolic BP of 120 to 157 mmHg had less than an 80 percent chance of correctly classifying the patient as being in or out of control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/17\">",
"     17",
"    </a>",
"    ]. Correct classification was maximized at five to six measurements, with most of the benefit occurring with the second measurement.&nbsp;",
"   </p>",
"   <p>",
"    If the BP is taken at home to establish the diagnosis of hypertension or to assess BP control, at least 12 to 14 measurements should be obtained, with both morning and evening measurements taken over one week. Home BP monitoring is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H16#H16\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Home BP measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Alternative sites for measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients whose BP cannot be measured using the upper arm, BP can be measured in the leg or wrist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Leg blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are occasional patients in whom the BP needs to be measured in the legs. The classic example is with suspected coarctation of the aorta in which there is an arm-to-leg gradient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link&amp;anchor=H1088178828#H1088178828\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Blood pressure and pulses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principles of BP measurement in the leg are similar to those described above in the arm. An appropriate-sized thigh cuff is essential. The systolic pressure in the leg in normal subjects is usually 10 to 20 percent higher than that in the brachial artery. Values more than 10 percent lower than brachial measurements have been used to screen for significant peripheral vascular disease. BP readings at the ankle obtained with a Doppler device have been used to obtain an ankle-brachial index (ABI) and shown to be an accurate indicator of peripheral vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H146789823#H146789823\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Lower extremity segmental pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Wrist blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although experience is relatively limited, measurement of BP at the wrist may be more practical in obese people and in patients with breast cancer who have had axillary lymph node resection.",
"   </p>",
"   <p>",
"    Systolic BP rises, and diastolic BP falls, in more distal arteries. In the wrist, the hydrostatic pressure related to the lower position of the wrist relative to the heart can result in a further false elevation of BP. This can be minimized by taking the BP with the wrist kept at the level of the heart. If they are to be used, they require similar calibration with office BP monitors as recommended for all BP machines.",
"   </p>",
"   <p>",
"    Devices that measure pressure in the finger are not recommended, including for home monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43080/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18374276\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension can be diagnosed using one of the following three acceptable measurement strategies (see",
"      <a class=\"local\" href=\"#H10945837\">",
"       'Methods for the diagnosis of hypertension'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ambulatory blood pressure monitoring (ABPM)",
"     </li>",
"     <li>",
"      Home blood pressure monitoring",
"     </li>",
"     <li>",
"      Office-based blood pressure measurements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABPM is determined using a device (worn by the patient) that takes blood pressure (BP) measurements over a 24- to 48-hour period, usually every 15 to 20 minutes during the daytime and every 30 to 60 minutes during sleep. These blood pressures are recorded on the device, and the average day (diurnal) or night (nocturnal) blood pressures are determined from the data by a computer. When ABPM is used, hypertension is defined as an average BP greater than or equal to",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H10945858\">",
"       'Ambulatory and home blood pressure monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ABPM has been considered to be the reference standard for the diagnosis of hypertension and is a better predictor of future cardiovascular events as compared with conventional office-based BP measurements. A patient with elevated office-based BP but normal 24-hour ambulatory BP is considered to have office hypertension or \"white coat\" hypertension. However, ABPM is not available in most clinicians' offices. (See",
"      <a class=\"local\" href=\"#H10945858\">",
"       'Ambulatory and home blood pressure monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In view of the cost and limited availability of ambulatory monitoring, home monitoring with inexpensive semi-automatic devices may be used. If the BP is taken at home to establish the diagnosis of hypertension or to assess BP control, at least 12 to 14 measurements should be obtained, with both morning and evening measurements taken, over a period of one week. When home BP monitoring is used, hypertension is defined as an average BP greater than or equal to",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      mmHg, identical to the definition used for ABPM. (See",
"      <a class=\"local\" href=\"#H10945925\">",
"       'Home blood pressure monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite advantages of ABPM, office-based BP measurement will likely continue to be the primary technique for both the diagnosis and management of hypertension in the United States and elsewhere, largely due to the lack of payment for ABPM or home BP monitors by most third-party payers and the unavailability of these techniques in some areas. (See",
"      <a class=\"local\" href=\"#H10945945\">",
"       'Office-based blood pressure measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The proper measurement of office-based BP requires attention to all of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Time of measurement &ndash; For office monitoring of antihypertensive therapy, the BP should optimally be measured at about the same time of day and before medications are taken to estimate the trough or nadir effect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Time of measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type of measurement device &ndash; Both mercury and aneroid sphygmomanometers are less widely used, the former because of mercury toxicity, the latter because of frequent inaccuracies. Thus, automated oscillometric BP (AOBP) measuring devices are increasingly being used in medical offices and are also used for home monitoring. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Type of measurement device'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2310063\">",
"       'Automated oscillometric BP measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cuff size &ndash; Use of a proper-sized cuff is essential. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cuff size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient position &ndash; The BP should be taken with the patient in a seated position with the back supported and legs uncrossed. The arm should be supported at the level of the heart. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patient position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cuff placement &ndash; The BP cuff should be placed with the bladder midline over the brachial artery pulsation, with the arm without restrictive clothing (the patient's sleeve should not be rolled up as this may act as a tourniquet). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cuff placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Technique of measurement &ndash; The BP should be measured initially in both arms. If automated devices are not being used, the pressure should be taken at least twice during each office visit, with the measurements separated by one to two minutes to allow the release of trapped blood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Technique of measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Number of measurements &ndash; In the absence of end-organ damage, the diagnosis of hypertension should not be made until the BP has been measured on at least three visits, spaced over a period of one week or more. In addition, multiple measurements are necessary when monitoring patients who are already on treatment for hypertension. (See",
"      <a class=\"local\" href=\"#H10946091\">",
"       'Need for multiple measurements'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/1\">",
"      Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/2\">",
"      Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/3\">",
"      Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ 2011; 342:d3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/4\">",
"      Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011; 378:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/5\">",
"      Staessen JA, Bieniaszewski L, O'Brien E, et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The \"Ad Hoc' Working Group. Hypertension 1997; 29:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/6\">",
"      Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005; 45:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/7\">",
"      Fujii T, Uzu T, Nishimura M, et al. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis 1999; 33:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/8\">",
"      Parati G, Pickering TG. Home blood-pressure monitoring: US and European consensus. Lancet 2009; 373:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/9\">",
"      Stergiou GS, Skeva II, Baibas NM, et al. Diagnosis of hypertension using home or ambulatory blood pressure monitoring: comparison with the conventional strategy based on repeated clinic blood pressure measurements. J Hypertens 2000; 18:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/10\">",
"      Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/11\">",
"      Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 2010; 24:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/12\">",
"      Niiranen TJ, Johansson JK, Reunanen A, Jula AM. Optimal schedule for home blood pressure measurement based on prognostic data: the Finn-Home Study. Hypertension 2011; 57:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/13\">",
"      Kleinert HD, Harshfield GA, Pickering TG, et al. What is the value of home blood pressure measurement in patients with mild hypertension? Hypertension 1984; 6:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/14\">",
"      Verberk WJ, Kroon AA, Kessels AG, de Leeuw PW. Home blood pressure measurement: a systematic review. J Am Coll Cardiol 2005; 46:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/15\">",
"      Mejia, AD, Egan, BM, Schork, NJ, Zweifler, AJ. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension, Ann Intern Med 1990; 112:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/16\">",
"      Veerman DP, van Montfrans GA, Wieling W. Effects of cuff inflation on self-recorded blood pressure. Lancet 1990; 335:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/17\">",
"      Powers BJ, Olsen MK, Smith VA, et al. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med 2011; 154:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/18\">",
"      Myers MG. A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertens 2010; 28:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/19\">",
"      Spranger CB, Ries AJ, Berge CA, et al. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med 2004; 117:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/20\">",
"      Beevers G, Lip GY, O'Brien E. ABC of hypertension: Blood pressure measurement. Part II-conventional sphygmomanometry: technique of auscultatory blood pressure measurement. BMJ 2001; 322:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/21\">",
"      Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/22\">",
"      Landgraf J, Wishner SH, Kloner RA. Comparison of automated oscillometric versus auscultatory blood pressure measurement. Am J Cardiol 2010; 106:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/23\">",
"      Myers MG, Godwin M. Automated office blood pressure. Can J Cardiol 2012; 28:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/24\">",
"      Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011; 342:d286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/25\">",
"      O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/26\">",
"      Beevers G, Lip GY, O'Brien E. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques. BMJ 2001; 322:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/27\">",
"      Zweifler AJ, Shahab ST. Pseudohypertension: a new assessment. J Hypertens 1993; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/28\">",
"      Jamieson MJ, Webster J, Philips S, et al. The measurement of blood pressure: sitting or supine, once or twice? J Hypertens 1990; 8:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/29\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/30\">",
"      O'Brien, E. Ambulatory blood pressure measurement is indispensible to good clinical practice. J Hypertens 2003; 21(suppl 2):S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/31\">",
"      Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA 1988; 259:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/32\">",
"      Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/33\">",
"      Ma G, Sabin N, Dawes M. A comparison of blood pressure measurement over a sleeved arm versus a bare arm. CMAJ 2008; 178:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/34\">",
"      Cavallini MC, Roman MJ, Blank SG, et al. Association of the auscultatory gap with vascular disease in hypertensive patients. Ann Intern Med 1996; 124:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/35\">",
"      Tholl U, Forstner K, Anlauf M. Measuring blood pressure: pitfalls and recommendations. Nephrol Dial Transplant 2004; 19:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/36\">",
"      Wang JG, Staessen JA, Messaggio E, et al. Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 2003; 21:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/37\">",
"      Bailey RH, Bauer JH. A review of common errors in the indirect measurement of blood pressure. Sphygmomanometry. Arch Intern Med 1993; 153:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/38\">",
"      Gosse P. Blood pressure should be measured in both arms on the first consultation. J Hypertens 2002; 20:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/39\">",
"      Betensky BP, Jaeger JR, Woo EY. Unequal blood pressures: a manifestation of subclavian steal. Am J Med 2011; 124:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/40\">",
"      Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012; 379:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/41\">",
"      U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007; 147:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/42\">",
"      Hartley RM, Velez R, Morris RW, et al. Confirming the diagnosis of mild hypertension. Br Med J (Clin Res Ed) 1983; 286:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43080/abstract/43\">",
"      Allison MA, Hiatt WR, Hirsch AT, et al. A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. J Am Coll Cardiol 2008; 51:1292.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3879 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3D38DFFA37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43080=[""].join("\n");
var outline_f42_4_43080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18374276\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10945837\">",
"      METHODS FOR THE DIAGNOSIS OF HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10945858\">",
"      AMBULATORY AND HOME BLOOD PRESSURE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10945925\">",
"      Home blood pressure monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6381476\">",
"      - Cuff inflation hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10945945\">",
"      OFFICE-BASED BLOOD PRESSURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Time of measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type of measurement device",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2310063\">",
"      - Automated oscillometric BP measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cuff size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pseudohypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cuff placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Technique of measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10946091\">",
"      Need for multiple measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Alternative sites for measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Leg blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Wrist blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18374276\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3879|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/2/24621\" title=\"figure 1\">",
"      BP by doctor and nurse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/49/29469\" title=\"figure 2\">",
"      Persistent white coat HTN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/32/44556\" title=\"table 1\">",
"      Measurement of BP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38375?source=related_link\">",
"      Cardiovascular effects of caffeine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3395?source=related_link\">",
"      Smoking and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_4_43081="Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease";
var content_f42_4_43081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Justin B Lundbye, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43081/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/4/43081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress radionuclide myocardial perfusion imaging (rMPI) can be used to demonstrate the presence of coronary heart disease (CHD) and to risk stratify and guide management of patients with known disease. Treadmill or bicycle exercise is the",
"    <strong>",
"     preferred",
"    </strong>",
"    form of stress for patients who can attain an adequate level of exercise (defined as &ge;85 percent of their predicted maximal heart rate). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many patients (particularly those who are elderly) are unable to exercise to an adequate level or have contraindications to such testing. Inadequate exercise may lead to an underestimation of the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of CHD. In addition to reducing symptoms and electrocardiographic (ECG) changes, submaximal exercise may reduce the diagnostic accuracy of exercise rMPI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical use of vasodilator stress rMPI for the diagnosis of CHD, for prognosis, and for use in specific settings will be reviewed here. Issues specific to the different pharmacologic agents, such as study protocol, safety, contraindications, and drug interactions, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress rMPI, pharmacologic stress echocardiography, and general discussions on the use of stress testing for the diagnosis and prognosis of known or suspected CHD, including its prognostic role after an acute coronary syndrome or revascularization, and the advantages and limitations of the different stress tests are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42134?source=see_link\">",
"     \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20138?source=see_link\">",
"     \"Role of stress testing after coronary revascularization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF TEST MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice among the different types of stress tests is based upon the patient's ability to exercise to a level high enough to produce meaningful results on exercise ECG testing, the possible presence of baseline electrocardiographic abnormalities that could interfere with the interpretation of exercise ECG testing, and whether or not it is important to localize ischemia or assess myocardial viability (",
"    <a class=\"graphic graphic_algorithm graphicRef87155 \" href=\"mobipreview.htm?26/46/27363\">",
"     algorithm 1",
"    </a>",
"    ). As noted above, treadmill or bicycle exercise is the preferred stress modality in patients who are able to exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comparison of test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have compared the performance of the following tests in patients with an intermediate pretest risk of CHD (25 to 75 percent): exercise ECG testing, planar thallium rMPI, SPECT (single-photon emission computed tomography) rMPI, stress echocardiography, and positron emission tomography (PET), each of which was followed by coronary angiography if the test was positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. One limitation of these analyses is that they include older studies so findings do not reflect currently available technological improvements in imaging.",
"   </p>",
"   <p>",
"    The following values for sensitivity and specificity were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise ECG testing &ndash; 68 and 77 percent in 132 studies of over 24,000 patients.",
"     </li>",
"     <li>",
"      Planar thallium rMPI (including both exercise and pharmacologic testing) &ndash; 79 and 73 percent in six studies of 510 patients.",
"     </li>",
"     <li>",
"      Thallium SPECT rMPI (including both exercise and pharmacologic testing) &ndash; 88 and 77 percent in eight studies of 628 patients.",
"     </li>",
"     <li>",
"      Stress echocardiography - 76 and 88 percent in 10 studies of 1174 patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac PET rMPI (pharmacologic stress only) &ndash; 92 and 85 percent in 19 studies of 1442 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of studies have compared simultaneous stress echocardiography and stress rMPI. The overall accuracy of the two techniques was comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative accuracy of stress echocardiography and stress rMPI may be influenced by certain patient characteristics. As examples, stress echocardiography appears to be more accurate than stress rMPI in patients with left ventricular hypertrophy, while vasodilator stress rMPI may be superior in patients with high body mass index. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link&amp;anchor=H15#H15\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Left ventricular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac PET perfusion imaging has grown in use and has a high overall accuracy. A metaanalysis by Nandular et al, demonstrated a sensitivity of 92 percent and a specificity of 85 percent for the diagnosis of obstructive CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/7\">",
"     7",
"    </a>",
"    ]. In some studies cardiac PET is reported to be superior than SPECT and in particular seems to improve diagnostic certainty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Choice of pharmacologic stress agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo pharmacologic stress rMPI, a separate issue is the relative performance of the different agents used in pharmacologic stress echocardiography for the diagnosis of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This issue was addressed in a 2001 regression meta-analysis of 82 studies involving 10,817 patients with angiographic data who underwent pharmacologic stress echocardiography or single photon emission computed tomography (SPECT) rMPI using adenosine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . When used for rMPI, the three drugs had similar sensitivity and specificity for the diagnosis of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     Regadenoson",
"    </a>",
"    does not have sensitivity or specificity data, but compared to adenosine the diagnostic accuracy is comparable. In a phase three multicenter clinical trial regadenoson was not found to be inferior to adenosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/15\">",
"     15",
"    </a>",
"    ]. Adenosine, regadenoson or dipyridamole are the first choice for pharmacologic stress rMPI, although local availability and expertise may be important (",
"    <a class=\"graphic graphic_algorithm graphicRef87155 \" href=\"mobipreview.htm?26/46/27363\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three vasodilators used for pharmacologic rMPI are adenosine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef71371 \" href=\"mobipreview.htm?3/42/3757\">",
"     table 1",
"    </a>",
"    ). These drugs produce primary coronary vasodilation that is mediated by the A2A adenosine receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/16\">",
"     16",
"    </a>",
"    ]. The mechanisms by which these vasodilators generate perfusion defects is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link&amp;anchor=H5#H5\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\", section on 'Mechanism of vasodilator stress'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are equally effective diagnostically, but adenosine has the advantages of a very short half-life, rapid reversal of side effects after the test is completed and possibly more predictable vasodilation. On the other hand, because of its longer half-life, patients can receive a dipyridamole infusion and then undergo any level of supplemental exercise.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     Regadenoson",
"    </a>",
"    , because of its pharmacokinetics may also be used in combination with exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenosine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are contraindicated in patients with resting hypotension (since these drugs lower the blood pressure), sick sinus syndrome or high degree atrioventricular (AV) block in the absence of backup pacing, and in patients receiving oral dipyridamole therapy. There is an increased risk for ischemic events in patients with an acute coronary syndrome, and stress imaging with vasodilators should be avoided in these settings, or if necessary, used cautiously.",
"   </p>",
"   <p>",
"    Available data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and to a lesser extent, caffeine, alter the hemodynamic response to these drugs, since both are adenosine receptor antagonists. The 2003 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines recommended that patients not use theophylline or ingest products containing caffeine for 24 hours prior to adenosine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a subsequent study found that one cup of coffee one hour before testing did not interfere with adenosine SPECT perfusion imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link&amp;anchor=H10#H10\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\", section on 'Vasodilator agents'",
"    </a>",
"    .) In a phase II double blinded, randomized, controlled trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    -induced coronary flow reserve was not affected by caffeine ingestion two hours prior to the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another concern is bronchospastic airway disease since adenosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stimulate the A1, A2B, and A3 adenosine receptors, which are related to bronchospasm. Adenosine and dipyridamole should generally NOT be used in this setting, even though bronchospasm may be promptly reversed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link&amp;anchor=H23#H23\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\", section on 'Contraindications to vasodilators'",
"    </a>",
"    .) In contrast, preliminary data suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    may be tolerated in patients with mild to moderate asthma because of its much greater A2A selectivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/20\">",
"     20",
"    </a>",
"    ]. While encouraging, it is not currently recommended to use regadenoson in asthmatic patients. Side effects of regadenoson in patients with chronic obstructive pulmonary disease were comparable to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are also associated with a number of subjective side effects such as chest pain, dyspnea, and flushing that are thought to be due at least in part to nonspecific adenosine receptor activation. The potential use of selective A2A adenosine receptor agonists to avoid such side effects is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link&amp;anchor=H15#H15\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\", section on 'Selective A2A receptor agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium channel blockers, nitrates, or beta blockers administered before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or adenosine imaging can alter the extent and severity of perfusion defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As a result, the extent and or presence of coronary disease may be underestimated when these drugs are given. Thus, such agents should be discontinued for 24 hours before the test (48 hours for beta blockers), unless there is a contraindication or the specific purpose of the test is to assess the efficacy of the antiischemic drug therapy. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19946?source=see_link\">",
"     \"Impact of medications and methylxanthines on stress testing\"",
"    </a>",
"    .) The interaction, or the lack thereof, of calcium channel blockers, nitrates, or beta blockers has not been studied in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    but it is suggested to use a similar approach as adenosine and dipyridamole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dobutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    is indicated as a stress agent in patients who are not candidates for vasodilator stress testing including those with reactive airways disease or those who have recently taken",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    or have recent significant caffeine intake (",
"    <a class=\"graphic graphic_table graphicRef71371 \" href=\"mobipreview.htm?3/42/3757\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42134?source=see_link\">",
"     \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"    </a>",
"    .) Recent beta-blocker therapy limits the use of dobutamine stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary and ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who are unable to exercise to a level which produces meaningful results, vasodilator stress rMPI or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography is most often recommended. Overall test performance is similar with these approaches. As a result, the choice between rMPI and echocardiography should be based upon local availability and expertise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    Task Force on chronic stable angina published recommendations for the use of stress imaging as the initial test for diagnosis or for risk assessment in patients who can or cannot exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/3\">",
"     3",
"    </a>",
"    ]. When used for diagnosis, stress testing is primarily of value in patients with an",
"    <strong>",
"     intermediate",
"    </strong>",
"    pretest probability (variably defined as between 25 and 75 percent or between 10 and 90 percent) of CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Pretest probability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines concluded that there was evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general agreement (class I) that pharmacologic stress be used as the",
"    <strong>",
"     initial test",
"    </strong>",
"    for diagnosis or risk stratification in patients with known or suspected CHD in a variety of settings. The following recommendations apply for patients who are",
"    <strong>",
"     unable",
"    </strong>",
"    to exercise (",
"    <a class=\"graphic graphic_table graphicRef74428 graphicRef61603 graphicRef52995 \" href=\"mobipreview.htm?37/52/38734\">",
"     table 2A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenosine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      rMPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography for diagnosis in patients with an intermediate pretest probability of CHD and, for prognosis, to identify the extent, severity, and location of ischemia in patients who do not have left bundle branch block or a paced ventricular rhythm.",
"     </li>",
"     <li>",
"      When used for diagnosis, adenosine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      rMPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography in patients with prior revascularization; when used for prognosis, adenosine or dipyridamole rMPI or dobutamine echocardiography to assess the functional significance of coronary lesions, if not already known, prior to percutaneous coronary intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Separate recommendations apply for patients with left bundle branch block or paced ventricular rhythm, whether or not they are able to exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasodilator rMPI is recommended in patients with a paced ventricular rhythm, unless the patient is known to demonstrate return of native ECG conduction with exercise.",
"     </li>",
"     <li>",
"      The 2009",
"      <span class=\"nowrap\">",
"       AHA/ACC",
"      </span>",
"      perioperative guidelines recommend vasodilator stress rMPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography in patients who cannot exercise or in patients who have a left bundle branch block on ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    rMPI was not recommended as a method of pharmacologic stress for either diagnosis or prognosis by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines. However, there are considerable data confirming the usefulness of this modality in both diagnosis and risk stratification (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42134?source=see_link\">",
"     \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    was not recommended because it was not FDA approved at the time but should be considered equivalent to adenosine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section will emphasize the use of vasodilator stress rMPI in the diagnosis and risk stratification of patients with known or suspected CHD. The use of these tests in other clinical settings is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For risk stratification after an acute coronary syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6678?source=see_link\">",
"       \"Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For diagnosis of restenosis or disease progression and risk stratification after coronary revascularization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20138?source=see_link\">",
"       \"Role of stress testing after coronary revascularization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the assessment of myocardial viability and hibernation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=see_link\">",
"       \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the physiologic assessment of intermediate severity (40 to 70 percent) coronary artery stenosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13672?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical use of coronary artery pressure and Doppler flow measurements\", section on 'Comparison with rMPI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the preoperative assessment of patients with vascular disease prior to major noncardiac surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link&amp;anchor=H27#H27\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Noninvasive cardiac testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute rest rMPI for the diagnosis of an acute coronary syndrome is also discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3496?source=see_link\">",
"       \"Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     LBBB or paced ventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise perfusion imaging in patients with LBBB or a paced ventricular rhythm, which produces an LBBB pattern on the ECG, is associated with transient defects in the anteroseptal and septal regions in the absence of a lesion within the left anterior descending coronary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/31\">",
"     31",
"    </a>",
"    ]. As a result, vasodilator stress rMPI is preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vasodilator stress combined with exercise ECG testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;During exercise stress, the presence or absence of chest pain or ECG changes as well as exercise duration and other exercise parameters provide prognostic and interpretive assistance when combined with the results of imaging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, regardless of the type of pharmacologic stress used, chest pain and ECG changes occur less often than with exercise stress (",
"    <a class=\"graphic graphic_table graphicRef77326 \" href=\"mobipreview.htm?8/47/8957\">",
"     table 3",
"    </a>",
"    ), and exercise capacity as a marker of outcome as well as heart rate and blood pressure responses to exercise cannot be assessed. The absence of these prognostic indicators during pharmacologic stress places added importance on the accuracy of the imaging results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link&amp;anchor=H8#H8\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\", section on 'ST segment depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, when possible, submaximal treadmill exercise ECG testing is performed in some laboratories in conjunction with vasodilator stress rMPI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. This combined approach has the advantages of reducing noncardiac side effects associated with pharmacologic stress (",
"    <a class=\"graphic graphic_table graphicRef77326 \" href=\"mobipreview.htm?8/47/8957\">",
"     table 3",
"    </a>",
"    ) and improving image quality by decreasing liver activity and providing prognostic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Adding exercise to the vasodilator does not further increase coronary blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], but does provide a better assessment of exercise capacity and may provide additional clinical information from the exercise ECG test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/32\">",
"     32",
"    </a>",
"    ]. This approach may make nondiagnostic tests less likely in patients with limited exercise capacity compared to exercise alone.",
"   </p>",
"   <p>",
"    The potential benefits of combined testing were illustrated in a study in which 407 patients were randomly assigned to six minutes of adenosine infusion alone, six minutes of adenosine with submaximal exercise, or symptom-limited exercise with continuous adenosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/33\">",
"     33",
"    </a>",
"    ]. The sensitivity and specificity for the detection of coronary disease or of stenosis in individual coronary arteries were similar in the three groups; however, the combined protocols were associated with a 43 percent reduction in noncardiac side effects related to vasodilation and a 90 percent reduction in major arrhythmias compared to adenosine infusion alone.",
"   </p>",
"   <p>",
"    When combined with adenosine stress rMPI, exercise must be performed concurrent with the usually six minute adenosine infusion, because of the short duration of the action of adenosine (",
"    <a class=\"graphic graphic_figure graphicRef60268 \" href=\"mobipreview.htm?30/2/30766\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In contrast, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress rMPI, exercise can be started after the dipyridamole infusion is completed since it has a longer hyperemic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/32\">",
"     32",
"    </a>",
"    ]; exercise can then continue until the protocol is completed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\"",
"    </a>",
"    .) Likewise, combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    with low-level stress testing is well tolerated and associated with fewer side effects when compared to adenosine infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/41\">",
"     41",
"    </a>",
"    ]. Regadenoson also has the advantage of being administered as a bolus immediately at the end of the exercise when the patient has to stop at a submaximal endpoint before radiotracer has been administered.",
"   </p>",
"   <p>",
"    Adenosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    generally produce similar results when combined with submaximal exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/35\">",
"     35",
"    </a>",
"    ]. When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    or adenosine is combined with exercise, the image quality is improved without any change in diagnostic accuracy of the exercise test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/33,34,36,41\">",
"     33,34,36,41",
"    </a>",
"    ]. In comparison, dipyridamole plus exercise may improve the detection of ischemia and assessment of its severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/37\">",
"     37",
"    </a>",
"    ], although data are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis of CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used for diagnosis, stress testing is primarily of value in patients with an",
"    <strong>",
"     intermediate",
"    </strong>",
"    pretest probability (variably defined as between 25 and 75 percent or between 10 and 90 percent) of CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Pretest probability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, exercise is the preferred stress for the diagnosis of CHD and pharmacologic stress is primarily warranted in patients who are unable to perform a maximal exercise test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] In addition to perfusion defects, pharmacologic stress testing can also induce chest pain and ST segment depression or elevation (",
"    <a class=\"graphic graphic_table graphicRef77326 \" href=\"mobipreview.htm?8/47/8957\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients undergoing pharmacologic stress rMPI, the sensitivity and specificity for diagnosis are generally comparable with adenosine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress rMPI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/13\">",
"     13",
"    </a>",
"    ]. There are no diagnostic data available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    . However, in the ADVANCE trial, a phase 3 study comparing regadenoson to adenosine, side-by-side interpretation of regadenoson and adenosine images provided comparable results for detecting reversible defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice between pharmacologic rMPI and echocardiography should be based upon local availability and expertise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Summary and ACC/AHA guidelines'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prognosis of CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic usefulness of pharmacologic stress rMPI appears to be comparable to that of exercise stress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Prognostic efficacy has been described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], adenosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/47\">",
"     47",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/27-30,48\">",
"     27-30,48",
"    </a>",
"    ]. Navare et al, in a meta-analysis, demonstrated that exercise stress rMPI and pharmacologic stress rMPI are comparable in their ability to risk-stratify patients. However, patients undergoing pharmacologic stress studies are at a higher risk for subsequent cardiac events. It has not yet been evaluated using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    rMPI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse predictors of future cardiac events after pharmacologic stress include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large defect size (&gt;20 percent of the left ventricle)",
"     </li>",
"     <li>",
"      Defects in more than one coronary artery territory, suggestive of multivessel CHD",
"     </li>",
"     <li>",
"      Major nonreversible defects",
"     </li>",
"     <li>",
"      Transient or fixed left ventricular cavity dilatation",
"     </li>",
"     <li>",
"      Resting left ventricular ejection fraction &lt;40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk stratification with adenosine rMPI is similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    . Among 1159 patients with known or suspected CHD who were followed for 28 months, adenosine stress rMPI added incremental prognostic value over clinical and historic data and permitted accurate risk stratification into low, intermediate, and high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients with a normal or mildly abnormal scan had a low risk for cardiac death compared to those with moderately or severely abnormal scans (&lt;1 versus 3.4 and 7.4 percent per year of follow-up, respectively). A similar relationship was seen with nonfatal cardiac event rates.",
"   </p>",
"   <p>",
"    A later and larger study from the same group derived and then validated a prognostic score that incorporated clinical risk factors (eg, older age, diabetes, resting heart rate, dyspnea as a presenting symptom) and certain findings on adenosine rMPI (eg, percent myocardium that was ischemic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The score was able to further stratify patients with normal, mildly abnormal, or moderate to severely abnormal tests, defined as involvement of less than 5 percent, 5 to 10 percent, and more than 10 percent of the myocardium involved with ischemic, or fixed defects. The mean follow-up was 2.2 years.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a normal adenosine rMPI, the yearly cardiac mortality rate varied from 0.4 to 5.3 percent per year in patients with a low and high prognostic score, respectively.",
"     </li>",
"     <li>",
"      Among patients with a moderate to severely abnormal adenosine rMPI, the yearly cardiac mortality rate varied from 3.9 to 7.6 percent per year in patients with a low and high prognostic score, respectively.",
"     </li>",
"     <li>",
"      The prognostic score also identified patients having more than 2.5 or 5 percent predicted improvement in survival with revascularization. The benefit increases with increasing amounts of inducible ischemia, while patients with fixed (nonreversible) defects are not likely to benefit. In another report from the same investigators, mortality was significantly lower with revascularization in patients with ischemia involving more than 10 percent of total myocardium (2.6 versus 5.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link&amp;anchor=H8#H8\">",
"       \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Strongly positive stress test'",
"      </a>",
"      .) These data must be considered in the context that it was retrospective and nonrandomized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Regadenoson",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no data available for prognostication using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    , but there is no reason to think it would be different than adenosine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    rMPI was demonstrated in a series of 512 patients in whom an abnormal scan was associated with a higher incidence of cardiac events during a 13 month follow-up, particularly when reversible defects were present (8.6 versus 1.4 percent without reversible defects) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with large defects, suggestive of multivessel disease, had a higher rate of cardiac events and hospitalization for cardiac disease compared to those with a normal scan or abnormal scan with smaller defects.",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 516 patients undergoing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress testing with thallium-201 imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/44\">",
"     44",
"    </a>",
"    ]. During a mean follow-up of 21 months, patients with an abnormal image had a significantly higher risk for cardiac death or nonfatal myocardial infarction than those with a normal study (relative risk 3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk stratification by SPECT rMPI was evaluated in a population of 1652 predominantly male patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/52\">",
"     52",
"    </a>",
"    ]. Chronic kidney disease (CKD, defined as estimated globular filtration rate &lt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2) was present in 36 percent of subjects. Adenosine (68 percent of patients) or exercise SPECT rMPI was performed. The presence of either scar or ischemia was strongly predictive of cardiac death across the range of renal dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With CKD and a normal test, the annual cardiac death rate was 2.7 percent; with no CKD and a normal test, the annual cardiac death rate was significantly lower (0.8 percent).",
"     </li>",
"     <li>",
"      With CKD and scar, the annual cardiac death rate was 5.3 percent; with no CKD and scar, the annual cardiac death rate was significantly lower (2.5 percent).",
"     </li>",
"     <li>",
"      With CKD and ischemia, the annual cardiac death rate was 11 percent; with no CKD and ischemia, the annual cardiac death rate was significantly lower (4.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both CKD and abnormal rMPI test result (scar or ischemia) were independent predictors of cardiac death after accounting for risk factors, left ventricular dysfunction, pharmacological stress, and symptom status.",
"   </p>",
"   <p>",
"    Although risk stratification using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    stress testing has not yet been evaluated, a study evaluating the safety of regadenoson in patients with end-stage renal disease found that the drug was well tolerated, and the hemodynamic and side effect profiles were similar to those of patients with normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43081/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice among the different types of stress tests is based upon the patient's ability to exercise adequately, the presence of ST segment abnormalities making interpretation of ECG unreliable, left bundle branch block (LBBB), and local expertise (",
"      <a class=\"graphic graphic_algorithm graphicRef87155 \" href=\"mobipreview.htm?26/46/27363\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"       Regadenoson",
"      </a>",
"      , adenosine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      have similar sensitivity and specificity for the diagnosis of CHD. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Comparison of test performance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcium channel blockers, nitrates, or beta blockers may alter the results of stress testing (ST-segment response, reversible perfusion defects, and transient wall motion abnormalities). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vasodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical use of vasodilator stress radionuclide myocardial perfusion imaging (rMPI) is similar to that of exercise MPI. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With exercise rMPI, LBBB pattern on the ECG may be associated with reversible perfusion defects in the anteroseptal region in the absence of a lesion in the left anterior descending coronary artery. Therefore, vasodilator stress rMPI is preferred. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'LBBB or paced ventricular rhythm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combining low-level exercise with vasodilator stress rMPI improves image quality and decreases side effects. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Vasodilator stress combined with exercise ECG testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognostic usefulness of pharmacologic stress rMPI is similar to exercise rMPI. Important indicators of poor outcome include a large reversible perfusion defect, defects in more than one coronary artery territory, a large fixed defect, left ventricular cavity dilatation, and depressed left ventricular ejection fraction. In general, however, the event rates are higher in patients who undergo pharmacological stress rMPI than exercise rMPI, including those with normal perfusion pattern. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis of CHD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/1\">",
"      Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol 1989; 14:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/2\">",
"      Baudhuin T, Marwick T, Melin J, et al. Diagnosis of coronary artery disease in elderly patients: safety and efficacy of dobutamine echocardiography. Eur Heart J 1993; 14:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/3\">",
"      el-Said ES, Roelandt JR, Fioretti PM, et al. Abnormal left ventricular early diastolic filling during dobutamine stress Doppler echocardiography is a sensitive indicator of significant coronary artery disease. J Am Coll Cardiol 1994; 24:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/4\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/5\">",
"      Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/6\">",
"      Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999; 130:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/7\">",
"      Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: a meta-analysis. Acad Radiol 2008; 15:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/8\">",
"      Marwick T, D'Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/9\">",
"      Forster T, McNeill AJ, Salustri A, et al. Simultaneous dobutamine stress echocardiography and technetium-99m isonitrile single-photon emission computed tomography in patients with suspected coronary artery disease. J Am Coll Cardiol 1993; 21:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/10\">",
"      Mairesse GH, Marwick TH, Vanoverschelde JL, et al. How accurate is dobutamine stress electrocardiography for detection of coronary artery disease? Comparison with two-dimensional echocardiography and technetium-99m methoxyl isobutyl isonitrile (mibi) perfusion scintigraphy. J Am Coll Cardiol 1994; 24:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/11\">",
"      Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/12\">",
"      Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006; 48:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/13\">",
"      Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis. Am Heart J 2001; 142:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/14\">",
"      Marwick T, Willemart B, D'Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 1993; 87:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/15\">",
"      Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/16\">",
"      Udelson JE, Heller GV, Wackers FJ, et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 2004; 109:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/17\">",
"      Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/18\">",
"      Zoghbi GJ, Htay T, Aqel R, et al. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol 2006; 47:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/19\">",
"      Gaemperli O, Schepis T, Koepfli P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008; 51:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/20\">",
"      Leaker BR, O'Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/21\">",
"      Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/22\">",
"      Sharir T, Rabinowitz B, Livschitz S, et al. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. J Am Coll Cardiol 1998; 31:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/23\">",
"      Taillefer R, Ahlberg AW, Masood Y, et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003; 42:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/24\">",
"      B&oslash;ttcher M, Refsgaard J, Madsen MM, et al. Effect of antianginal medication on resting myocardial perfusion and pharmacologically induced hyperemia. J Nucl Cardiol 2003; 10:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/25\">",
"      Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001; 344:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/26\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/27\">",
"      Geleijnse ML, Elhendy A, Fioretti PM, Roelandt JR. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000; 36:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/28\">",
"      Senior R, Raval U, Lahiri A. Prognostic value of stress dobutamine technetium-99m sestamibi single-photon emission computed tomography (SPECT) in patients with suspected coronary artery disease. Am J Cardiol 1996; 78:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/29\">",
"      Geleijnse ML, Elhendy A, van Domburg RT, et al. Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol 1996; 28:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/30\">",
"      Calnon DA, McGrath PD, Doss AL, et al. Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imaging: stratification of a high-risk population. J Am Coll Cardiol 2001; 38:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/31\">",
"      Vaduganathan P, He ZX, Raghavan C, et al. Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block: exercise, adenosine or dobutamine imaging? J Am Coll Cardiol 1996; 28:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/32\">",
"      Casale PN, Guiney TE, Strauss HW, Boucher CA. Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging. Am J Cardiol 1988; 62:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/33\">",
"      Pennell DJ, Mavrogeni SI, Forbat SM, et al. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995; 25:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/34\">",
"      Thomas GS, Prill NV, Majmundar H, et al. Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol 2000; 7:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/35\">",
"      Cramer MJ, Verzijlbergen JF, van der Wall EE, et al. Comparison of adenosine and high-dose dipyridamole both combined with low-level exercise stress for 99Tcm-MIBI SPET myocardial perfusion imaging. Nucl Med Commun 1996; 17:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/36\">",
"      Jamil G, Ahlberg AW, Elliott MD, et al. Impact of limited treadmill exercise on adenosine Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging in coronary artery disease. Am J Cardiol 1999; 84:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/37\">",
"      Stein L, Burt R, Oppenheim B, et al. Symptom-limited arm exercise increases detection of ischemia during dipyridamole tomographic thallium stress testing in patients with coronary artery disease. Am J Cardiol 1995; 75:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/38\">",
"      Rossen JD, Simonetti I, Marcus ML, Winniford MD. Coronary dilation with standard dose dipyridamole and dipyridamole combined with handgrip. Circulation 1989; 79:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/39\">",
"      M&uuml;ller P, Czernin J, Choi Y, et al. Effect of exercise supplementation during adenosine infusion on hyperemic blood flow and flow reserve. Am Heart J 1994; 128:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/40\">",
"      Czernin J, Auerbach M, Sun KT, et al. Effects of modified pharmacologic stress approaches on hyperemic myocardial blood flow. J Nucl Med 1995; 36:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/41\">",
"      Thomas GS, Thompson RC, Miyamoto MI, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/42\">",
"      Navare SM, Mather JF, Shaw LJ, et al. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol 2004; 11:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/43\">",
"      Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004; 11:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/44\">",
"      Hendel RC, Layden JJ, Leppo JA. Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease. J Am Coll Cardiol 1990; 15:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/45\">",
"      Heller GV, Herman SD, Travin MI, et al. Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions. J Am Coll Cardiol 1995; 26:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/46\">",
"      Stratmann HG, Tamesis BR, Younis LT, et al. Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. Am J Cardiol 1994; 73:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/47\">",
"      Hachamovitch R, Berman DS, Kiat H, et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Am J Cardiol 1997; 80:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/48\">",
"      Geleijnse ML, Elhendy A, van Domburg RT, et al. Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. Am J Cardiol 1996; 77:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/49\">",
"      Hachamovitch R, Hayes SW, Friedman JD, et al. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol 2005; 45:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/50\">",
"      Udelson JE, Selker HP. Quantitative instruments for predicting risk ... and benefit. J Am Coll Cardiol 2005; 45:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/51\">",
"      Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/52\">",
"      Hakeem A, Bhatti S, Dillie KS, et al. Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation 2008; 118:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43081/abstract/53\">",
"      Aljaroudi W, Hermann D, Hage F, et al. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010; 105:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5302 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43081=[""].join("\n");
var outline_f42_4_43081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF TEST MODALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comparison of test performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Choice of pharmacologic stress agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dobutamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary and ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LBBB or paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vasodilator stress combined with exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prognosis of CHD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adenosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Regadenoson",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5302|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?26/46/27363\" title=\"algorithm 1\">",
"      Algorithm for choosing the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5302|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/2/30766\" title=\"figure 1\">",
"      Protocol adenosine stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5302|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/42/3757\" title=\"table 1\">",
"      Comparison pharm stress agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/46/33516\" title=\"table 2A\">",
"      ACC AHA choice imaging risk I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/22/21868\" title=\"table 2B\">",
"      ACC AHA choice imaging CHD diagnosis unable to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/42/18093\" title=\"table 2C\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/47/8957\" title=\"table 3\">",
"      Side effect pharm stress agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3496?source=related_link\">",
"      Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42134?source=related_link\">",
"      Dobutamine stress radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19946?source=related_link\">",
"      Impact of medications and methylxanthines on stress testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6678?source=related_link\">",
"      Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20138?source=related_link\">",
"      Role of stress testing after coronary revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_4_43082="Treatment of lower extremity deep vein thrombosis";
var content_f42_4_43082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of lower extremity deep vein thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/4/43082/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/4/43082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H412636\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep vein thrombosis (DVT) and acute pulmonary embolism (PE) are two manifestations of the same disorder, venous thromboembolism (VTE). DVT of the lower extremity, which will be discussed here, is subdivided into either distal (calf vein) or proximal (popliteal, femoral, or iliac vein) thrombosis. Proximal vein thrombosis is of greater importance clinically, since it is more commonly associated with serious, chronic disease (eg, active cancer, congestive failure, respiratory insufficiency, age &gt;75), whereas distal thrombosis is more often associated with transient risk factors (eg, recent surgery, immobilization, travel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/1\">",
"     1",
"    </a>",
"    ]. As a further example, over 90 percent of cases of acute PE are due to emboli emanating from the proximal, rather than the distal (ie, below the knee), veins of the lower extremities, and the mortality rate of proximal DVT is higher than that of distal DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VTE is an important cause of morbidity and mortality, particularly in hospitalized patients. PE is the cause of death or a major contributing factor in up to 16 percent of patients who die in the hospital. However, in some series, the diagnosis of PE is suspected before death in less than one-third of patients. It is therefore important to have a high index of suspicion for the presence of VTE and to initiate appropriate diagnostic tests and therapy. Primary prophylaxis with pharmacologic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mechanical methods should be used in patients with moderate to high risk of venous thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/2\">",
"     2",
"    </a>",
"    ]. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep vein thrombosis of the upper extremity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Ancillary information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the complexity of the issues surrounding diagnosis, screening, prevention, and treatment of VTE, we have provided the reader with an overview that can serve as a general introduction to all of the issues surrounding this subject. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More specific information on each of the aspects of this disorder is presented separately, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial evaluation &mdash; The initial approach to the patient with suspected or established venous thrombosis, with emphasis upon clinical features surrounding the event and the indications for testing (screening) for an inherited or acquired cause of thrombophilia, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"       \"Evaluation of the patient with established venous thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"       \"Overview of the causes of venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Establishing the diagnosis &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Upper extremity DVT &mdash; DVT occurs less frequently in the upper extremity than in the lower extremity, but the incidence is increasing because of greater use of indwelling central venous catheters, especially in patients with malignancy, who are prone to thrombotic complications. Prevention, complications, and treatment of upper extremity DVT, which generally differ from those employed for lower extremity DVT, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"       \"Catheter-induced upper extremity venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DVT in children &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14234?source=see_link\">",
"       \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention of VTE &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in medical patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"       \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of VTE in patients with malignancy including those with primary or secondary brain tumors &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link\">",
"       \"Treatment of venous thromboembolism in patients with malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of lower extremity superficial phlebitis &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/25/43417?source=see_link\">",
"       \"Superficial thrombophlebitis of the lower extremity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of DVT of the lower extremity, with an emphasis on the treatment of proximal DVT, will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ]. The treatment of pulmonary embolism and patient information on DVT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"     \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL OBJECTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objectives of treatment of DVT are to prevent the following: further clot extension, acute PE, recurrence of thrombosis, and the development of late complications, such as the post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevention of further thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy is indicated for patients with symptomatic proximal lower extremity DVT, since pulmonary embolism will occur in approximately 50 percent of untreated individuals, most often within days or weeks of the event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The benefit of anticoagulation was first suggested in 1960 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/6\">",
"     6",
"    </a>",
"    ] and confirmed by randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A mortality rate of less than 5 percent should be achieved with the use of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and oral anticoagulants; this may be further reduced with the use of low molecular weight heparin (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Low molecular weight heparin'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was shown in a 2010 meta-analysis of 13 prospective cohort studies and 56 randomized clinical trials, which indicated that the rates of recurrent VTE and recurrent fatal VTE during the first three months of anticoagulant therapy were 3.4 percent (95% CI 2.9-4.0) and 0.4 percent (95% CI 0.3-0.6), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/10\">",
"     10",
"    </a>",
"    ]. During this same interval the rates of major bleeding and major fatal bleeding were 1.6 percent (95% CI 1.3-2.0) and 0.2 percent (95% CI 0.1-0.3), respectively.",
"   </p>",
"   <p>",
"    Anticoagulation is usually achieved initially with unfractionated or low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , followed by oral anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a minimum of three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/11\">",
"     11",
"    </a>",
"    ]. As will be described below, the duration of warfarin therapy is determined in part by the presence or absence of persistent risk factors (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"mobipreview.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ) and whether the DVT represents a first or a recurrent episode. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention of post-thrombotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-thrombotic syndrome is the development of symptoms of venous insufficiency after DVT and eventually occurs in about 28 percent of patients who have had a symptomatic DVT. Prevention of this complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Testing for thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for thrombophilia in patients with established DVT, including interference with such testing caused by treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"mobipreview.htm?43/22/44396\">",
"     table 2",
"    </a>",
"    ), is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     UNFRACTIONATED HEPARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant response to a standard dose of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    varies widely among patients. Further, there is insufficient information in the literature to modify the initial dose according to estimates of the patient's \"wet\" versus \"dry\" weight or rapidly changing weight. This makes it necessary to monitor the response in each patient, using either the activated partial thromboplastin time (aPTT) or heparin levels, and to titrate the dose to the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy depends upon achieving a critical therapeutic level of heparin within the first 24 hours of treatment, usually via a continuous intravenous infusion of unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. The critical therapeutic level of heparin, as measured by the aPTT, is 1.5 times the mean of the control value or the upper limit of the normal aPTT range, with a target range (aPTT ratio) of 1.5 to 2.5. This corresponds to a heparin level of 0.3 to 0.7",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    when measured by an anti-Xa assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study, there was a threefold increase in the risk of recurrent venous thromboembolism in patients who were initially treated with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      infusion of 1000 international",
"      <span class=\"nowrap\">",
"       units/hour",
"      </span>",
"      and who had an aPTT ratio of &lt;1.5 times control for three days or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report evaluating patient groups entered into a series of three consecutive double-blind randomized trials, failure to achieve a therapeutic aPTT by 24 hours was associated with a 23.3 percent frequency of recurrent VTE compared with 4 to 6 percent for those whose aPTT exceeded the therapeutic threshold by 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional evidence for the importance of rapid adequate heparinization was reported in a randomized study conducted by the Galilei Investigators. Among patients allocated to receive UFH, recurrent thromboembolism occurred one-third as often (7 of 263 patients, 2.7 percent) in those who reached the aPTT therapeutic threshold within 24 hours, as compared with those who did not reach this threshold (8 of 97, 8.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is a strong correlation between subtherapeutic aPTT values and recurrent thromboembolism, the relationship between supratherapeutic aPTT (ie, an aPTT ratio 2.5 or more) and bleeding is less definite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is usually given simultaneously with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and is overlapped with warfarin for a minimum of four to five days until the International Normalized Ratio (INR) has been within the therapeutic range (2.0 to 3.0) for two consecutive days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/24\">",
"     24",
"    </a>",
"    ]. This overlap is required because, during the first few days of warfarin therapy, prolongation of the INR mainly reflects depression of factor VII, which has a half-life of only five to seven hours. Thus, although the extrinsic coagulation pathway is suppressed, the intrinsic coagulation pathway that does not require factor VII remains intact during this early period (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Warfarin'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    When combined with early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , four to five days of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy is as effective as 10 to 14 days of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In one trial of patients with proximal DVT, as an example, five and 10 days of heparin were associated with an equivalent incidence of recurrent venous thromboembolism (7.1 versus 7.0 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Administration and adequacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audits have shown that administration of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is fraught with difficulty and that the clinical practice of using an ad hoc approach to heparin dose-titration frequently results in inadequate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. As an example, an audit at three university-affiliated hospitals documented that 60 percent of treated patients failed to achieve an adequate aPTT response during the initial 24 hours of therapy and that 30 to 40 percent of patients remained subtherapeutic over the next three to four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased incidence of recurrent venous thromboembolism after inadequate initial heparinization has been described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/14,19\">",
"     14,19",
"    </a>",
"    ]. Several practices were identified that led to inadequate therapy. The common theme was fear of bleeding complications on the part of clinicians. These observations led to the initiation of protocols designed to avoid inadequate dosing. The value of these prescriptive or protocol approaches for administering intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy has been evaluated in two studies in patients with venous thromboembolism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first trial evaluated patients with proximal venous thrombosis who were given either intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      alone followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , or intravenous heparin and simultaneous warfarin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/23\">",
"       23",
"      </a>",
"      ]. The heparin nomogram used in this study is summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef66081 \" href=\"mobipreview.htm?43/40/44683\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72792 \" href=\"mobipreview.htm?21/6/21612\">",
"       table 4",
"      </a>",
"      ). Only 1 and 2 percent of the patients were subtherapeutic for more than 24 hours in the heparin group and in the heparin and warfarin group, respectively. Objectively documented recurrent venous thromboembolism occurred infrequently in both groups (7 percent), rates similar to those previously reported.",
"     </li>",
"     <li>",
"      The second trial compared a weight-based",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      dosing nomogram with a standard-care nomogram (",
"      <a class=\"graphic graphic_table graphicRef58483 \" href=\"mobipreview.htm?41/28/42444\">",
"       table 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients treated with the weight-adjusted regimen received a starting bolus dose of 80",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      followed by an 18",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour infusion. Patients in the standard-care group received a bolus of 5000 units followed by a 1000",
"      <span class=\"nowrap\">",
"       units/hour",
"      </span>",
"      infusion. The heparin dose was adjusted to maintain an aPTT of 1.5 to 2.3 times control. A higher percentage of patients in the weight-adjusted group achieved a therapeutic aPTT within 24 hours (97 versus 77 percent). The incidence of recurrent thromboembolism was much higher (relative risk: 5.0, 95% CI 1.1-21.9) in the standard-care group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We now routinely use the approach outlined in the second trial described above (",
"    <a class=\"graphic graphic_table graphicRef58483 \" href=\"mobipreview.htm?41/28/42444\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the two approaches yield comparable results (based on the cited studies), and either is acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LOW MOLECULAR WEIGHT HEPARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LMW heparins have a number of advantages over unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Greater bioavailability when given by subcutaneous injection",
"     </li>",
"     <li>",
"      Duration of the anticoagulant effect is greater, permitting once or twice daily administration.",
"     </li>",
"     <li>",
"      Anticoagulant response (anti-Xa activity) is highly correlated with body weight, permitting administration of a fixed dose.",
"     </li>",
"     <li>",
"      Laboratory monitoring is not necessary; in fact, there is little correlation between anti-Xa activity and either bleeding or recurrent thrombosis.",
"     </li>",
"     <li>",
"      Lower risk of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia compared with unfractionated heparin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, UFH may be preferred when cost is an issue, or because, unlike LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , its effect can be completely neutralized with protamine should bleeding become a problem.",
"   </p>",
"   <p>",
"    Subcutaneous, unmonitored LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been compared with continuous intravenous heparin for the treatment of proximal venous thrombosis in a number of clinical trials. LMW heparin, given once or twice daily, is at least as effective and safe as, and may be superior to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/33\">",
"     33",
"    </a>",
"    ], unfractionated heparin in patients with proximal venous thrombosis and may be associated with greater inhibition of in vivo thrombin generation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/34\">",
"     34",
"    </a>",
"    ], higher rates of thrombus regression, and lower rates of recurrent venous thromboembolism, major bleeding, and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one meta-analysis, LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was associated with a lower rate of both recurrent DVT (2.7 versus 7.0 percent) and major bleeding (0.9 versus 3.2 percent) than unfractionated heparin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second meta-analysis of 11 trials found a significantly lower mortality rate at three to six months among patients treated with LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      compared with those receiving unfractionated heparin (odds ratio: 0.71, 95% CI 0.53-0.94); differences in recurrent thromboembolism and bleeding complications were statistically",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinically insignificant between the two treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of five trials directly comparing LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      given once versus twice daily found no differences in symptomatic or asymptomatic recurrence of VTE between the two treatment schedules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/41\">",
"       41",
"      </a>",
"      ]. There were insufficient data in head-to-head studies to exclude the possibility of a higher frequency of fatal bleeding with once-daily treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The doses of the different LMW heparins have been established empirically and are not necessarily interchangeable. Accordingly, treatment regimens recommended specifically for each agent should be adhered to.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outpatient use",
"    </span>",
"    &nbsp;&mdash;&nbsp;A literature search of studies on the outpatient treatment of DVT has suggested that the following four criteria can help to identify patients with DVT for whom outpatient treatment might",
"    <strong>",
"     not",
"    </strong>",
"    be appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of massive DVT (eg, iliofemoral DVT)",
"     </li>",
"     <li>",
"      Presence of symptomatic pulmonary embolism",
"     </li>",
"     <li>",
"      High risk of bleeding with anticoagulant therapy",
"     </li>",
"     <li>",
"      Presence of comorbid conditions or other factors that warrant in-hospital care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, when feasible, patients with proximal DVT can be safely treated with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in an outpatient setting without loss of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/32,33,43-47\">",
"     32,33,43-47",
"    </a>",
"    ], thus avoiding hospitalization associated with use of unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/48\">",
"     48",
"    </a>",
"    ]. To insure safety of outpatient treatment with LMW heparin, patients should be stable, reliable, have a low risk of bleeding, and not have renal insufficiency (",
"    <a class=\"graphic graphic_table graphicRef70140 \" href=\"mobipreview.htm?16/35/16955\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example of this approach, 89 patients with acute DVT entered into an outpatient treatment protocol were treated with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for a median time of one day in a hospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/49\">",
"     49",
"    </a>",
"    ]. Following this, they received outpatient LMW heparin for a mean of 4.7 days, three months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and daily home nursing visits to monitor treatment and complications. Recurrent thromboembolism, major bleeding, and minor bleeding were noted in 1, 2, and 2 percent, respectively, with no deaths, and with an estimated cost saving of $1645 per patient.",
"   </p>",
"   <p>",
"    A meta-analysis of eight trials comparing outpatient use of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with inpatient unfractionated heparin found that the two treatments resulted in similar rates of recurrent DVT (4 versus 6 percent) and major bleeding (0.5 versus 1.0 percent), although use of LMW heparin was associated with shorter hospital stays (2.7 versus 6.5 days) and lower costs (median difference $1600) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/50\">",
"     50",
"    </a>",
"    ]. Comparisons of outpatient versus inpatient use of LMW heparin revealed no differences in outcomes, but outpatient use was more cost-effective, with a median difference in cost of 57 percent.",
"   </p>",
"   <p>",
"    A 2007 Cochrane analysis of six randomized controlled trials involving 1708 participants concluded that patients treated at home with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    were significantly less likely to have VTE recurrence (RR 0.61; 95% CI 0.42-0.90) than those treated in the hospital with unfractionated or LMW heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/51\">",
"     51",
"    </a>",
"    ]. Rates of mortality, major, and minor bleeding were not significantly different.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Long-term use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients unable or unwilling to use vitamin K antagonists after initial anticoagulation with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMW heparin, anticoagulation can be continued with LMW heparin without sacrificing effectiveness or causing increases in bleeding or overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/52\">",
"     52",
"    </a>",
"    ], and may result in a lowered frequency of post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, the use and acceptability of long-term LMW heparin will depend upon such variables as the clinical setting, patient comorbidity, ability of the patient or a family member to inject the medication, availability of health care resources, and reimbursement policies.",
"   </p>",
"   <p>",
"    Treatment with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may actually result in better outcomes than treatment with vitamin K antagonists in patients with acute VTE and malignancy. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H18#H18\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Treatment of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2012 Cochrane review of 15 trials of long term treatment of VTE with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    compared with vitamin K antagonists concluded that the former are as effective as vitamin K antagonists in preventing symptomatic VTE after an episode of symptomatic DVT (OR 0.82; 95% CI 0.59-1.13), but have the disadvantage of much higher costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/56\">",
"     56",
"    </a>",
"    ]. LMW heparin treatment resulted in significantly fewer episodes of bleeding (OR 0.50; 95% CI 0.31-0.79) with no difference in overall mortality (OR 1.06; 95% CI 0.74-1.54). The review concluded that LMW heparin is possibly a safe alternative to vitamin K antagonists in some patients, especially those in geographically inaccessible areas, are reluctant to visit a thrombosis service regularly, or have contraindications to treatment with vitamin K antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and meta-analyses of nonrandomized trials have indicated that the cost of treatment of acute DVT with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is similar to, or lower than, strategies utilizing unfractionated heparin, generally regardless of treatment setting (eg, inpatient versus outpatient) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/33,57-61\">",
"     33,57-61",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial analyzed the cost-effectiveness of standard intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      compared with LMW heparin in the treatment of acute proximal DVT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/57\">",
"       57",
"      </a>",
"      ]. There was a cost savings in favor of LMW heparin. It was further estimated that 37 percent of the patients in the study would have been eligible for outpatient therapy with LMW heparin, thereby increasing the cost savings for patients with proximal deep vein thrombosis.",
"     </li>",
"     <li>",
"      One decision analysis found similar costs for the inpatient use of unfractionated or LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for six days while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was initiated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/59\">",
"       59",
"      </a>",
"      ]. A decreased risk of early complications and a small increase in quality-adjusted life expectancy in the LMW heparin group translated into an incremental advantage of $7820 per quality-adjusted life year gained among these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , LMW heparin therapy should be overlapped with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a minimum of four to five days and until the INR has been within the therapeutic range (2.0 to 3.0) for two consecutive days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18424716\">",
"    <span class=\"h1\">",
"     FONDAPARINUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of this agent for the treatment of DVT is discussed separately. The 2012 ACCP Anticoagulation Guidelines for the initial treatment of DVT suggest the use of either LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    over intravenous or subcutaneous unfractionated heparin (Grade 2C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link&amp;anchor=H14#H14\">",
"     \"Therapeutic use of fondaparinux\", section on 'Initial treatment of venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THROMBOLYTIC THERAPY AND THROMBECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of thrombolytic therapy in the treatment of DVT is controversial, since most patients have an uncomplicated course when treated with unfractionated or low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/62\">",
"     62",
"    </a>",
"    ]. This issue is discussed in detail elsewhere and will be only briefly reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link&amp;anchor=H17#H17\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\", section on 'Lower extremity deep vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials with streptokinase and intravenous tissue-type plasminogen activator (tPA) suggest that the rate of lysis and likelihood of normal follow-up venography are greater with these agents than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. Greater degrees of clot lysis appear to be associated with a reduction in incidence of post-thrombotic syndrome, but this has not been proven definitively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/68\">",
"     68",
"    </a>",
"    ]. The randomized multicenter ATTRACT Study is currently underway to determine the safety and effectiveness of pharmacomechanical catheter-directed thrombolysis and whether it is sufficiently safe and effective to be recommended for routine use in patients with proximal DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/69\">",
"     69",
"    </a>",
"    ]. Bleeding may be more frequent among patients treated with thrombolytic therapy compared with heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear how many patients with DVT are actually candidates for thrombolytic therapy. One study, as an example, found that 194 of 209 patients (93 percent) had a contraindication to thrombolysis, most often recent surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/70\">",
"     70",
"    </a>",
"    ]. In addition, involvement of the patient in the decision is essential. In a decision analysis of 36 patients, all were unwilling to accept the small increase in death or disability due to bleeding just to prevent the post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assuming there are no absolute or relative contraindications, thrombolytic therapy, surgical thrombectomy, or percutaneous mechanical thrombectomy could be considered in patients with proximal occlusive DVT associated with significant swelling and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/69\">",
"     69",
"    </a>",
"    ]. If thrombolytic therapy is to be used, it should be started at the earliest opportunity. As in the treatment of acute myocardial infarction and stroke, the angiographic response to thrombolytic therapy is greatest when there is a shorter interval between the onset of symptoms and the initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link&amp;anchor=H7#H7\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Phlegmasia cerulea dolens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlegmasia cerulea dolens is an uncommon form of massive proximal (eg, iliofemoral) venous thrombosis of the lower extremities associated with a high degree of morbidity, including sudden severe pain with swelling, cyanosis, edema, venous gangrene, compartment syndrome, and arterial compromise, often followed by circulatory collapse and shock. Delay in treatment may result in death or loss of the patient's limb. Accordingly, catheter-directed thrombolysis or rapid removal of the occluding thrombus using manual techniques (eg, surgical thrombectomy) should be seriously considered for such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/7,63,73-76\">",
"     7,63,73-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link&amp;anchor=H17#H17\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\", section on 'Lower extremity deep vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INFERIOR VENA CAVA FILTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of an inferior vena cava (IVC) filter is generally employed in patients with acute venous thromboembolism who have an absolute contraindication to anticoagulant therapy (eg, recent surgery, hemorrhagic stroke, active bleeding), or who have recurrent VTE despite adequate anticoagulation. For those subjects who had an IVC filter placed because of a contraindication to the use of anticoagulants (ie, excess bleeding risk), we and others suggest a conventional course of anticoagulation therapy if the increased risk of bleeding resolves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other indications for an IVC filter are less well established. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     WARFARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of VTE with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    product is usually followed by at least a three- to six-month period of anticoagulation to prevent recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    (or another vitamin K antagonist) is highly effective for this purpose and is preferred in most patients. In patients with a proximal DVT, long-term therapy with warfarin reduces the frequency of objectively documented recurrent venous thromboembolism from 47 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Prolonged high dose subcutaneous unfractionated heparin or LMW heparin may be an equally effective alternative, especially in patients who are unable to take warfarin therapy.",
"   </p>",
"   <p>",
"    The anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , which is mediated by inhibition of the vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX, and X, is delayed until the normal clotting factors are cleared from the circulation. During the first few days of warfarin therapy, prolongation of the prothrombin time (INR) mainly reflects the depression of factor VII, which has a half-life of five to seven hours (",
"    <a class=\"graphic graphic_figure graphicRef50940 \" href=\"mobipreview.htm?26/56/27534\">",
"     figure 1",
"    </a>",
"    ). This does not represent adequate anticoagulation because the intrinsic clotting pathway remains intact until factors II, IX and X are sufficiently reduced, which takes about five days with adequate dosing. For this reason,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and warfarin treatment should overlap by four to five days when warfarin is initiated in patients with thrombotic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory test most commonly used to measure the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is the one-stage prothrombin time (PT). In order to promote standardization of the PT for monitoring oral anticoagulant therapy, the World Health Organization (WHO) developed an international reference thromboplastin from human brain tissue and recommended that the PT ratio be expressed as the International Normalized Ratio or INR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical use of coagulation tests\", section on 'Measurement of INR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dose and therapeutic range",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is generally administered in an initial oral dose of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first two days, with the daily dose then adjusted according to the INR.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is discontinued on the fourth or fifth day following initiation of warfarin therapy, provided the INR has been in the recommended therapeutic range for VTE (INR 2.0 to 3.0) for two consecutive days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/24\">",
"     24",
"    </a>",
"    ]. Attainment of an INR of 2.0 to 3.0 or its equivalent in patients with DVT markedly reduces the risk of bleeding (from 22 to 4 percent) compared with more intense regimens, without loss of effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/79\">",
"     79",
"    </a>",
"    ]; similar observations have been made in patients with atrial fibrillation (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"mobipreview.htm?42/18/43296\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because some individuals are either fast or slow metabolizers of the drug, and because increased age and other factors may alter the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the selection of",
"    <strong>",
"     initial",
"    </strong>",
"    and",
"    <strong>",
"     subsequent",
"    </strong>",
"    doses of warfarin must be individualized. Thus, frequent INR determinations are required initially to establish therapeutic anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of warfarin\", section on 'Initial dose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H24#H24\">",
"     \"Therapeutic use of warfarin\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the anticoagulant effect and patient's",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dose requirements are stable, the INR should be monitored every three to four weeks throughout the course of warfarin therapy for venous thromboembolism. More frequent monitoring is indicated if factors are present that may produce an unpredictable response to warfarin (eg, concomitant therapy with drugs that interact with warfarin). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H35#H35\">",
"     \"Therapeutic use of warfarin\", section on 'Excessive anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7479951\">",
"    <span class=\"h1\">",
"     OTHER ORALLY-ACTIVE ANTICOAGULANTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dabigatran and rivaroxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RE-COVER study was a randomized, double-blind, noninferiority trial involving 2539 patients with acute VTE, which compared 6 months of treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    (150 mg by mouth twice per day) or dose-adjusted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , after initial parenteral anticoagulation. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary outcome (recurrent symptomatic, objectively confirmed VTE and related deaths) was reached in 2.4 versus 2.1 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , respectively. The hazard ratio for dabigatran was 1.10 (95% CI 0.65-1.84).",
"     </li>",
"     <li>",
"      Major bleeding episodes occurred in 1.6 and 1.9 percent of those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , respectively, while episodes of any bleeding were noted in 16.1 and 21.9 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was concluded that a fixed dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    was as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for the treatment of acute VTE, with a safety profile similar to that of warfarin, without requiring laboratory monitoring.",
"   </p>",
"   <p>",
"    Systematic reviews of the available randomized trials (eg, EINSTEIN-DVT, EINSTEIN-PE, RE-COVER) on this subject have concluded that all-cause mortality and VTE-related mortality did not differ significantly between these two agents versus adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    when used in the long-term management of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/80-84\">",
"     80-84",
"    </a>",
"    ]. Their relative benefits in comparison with adjusted-dose warfarin in terms of bleeding risk were considered to be small and complicated by increasing reports of bleeding complications, particularly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , especially in older adults and those with renal impairment.",
"   </p>",
"   <p>",
"    Both agents are orally active and reach their peak efficacy within one to four hours following oral ingestion. Accordingly, a prolonged period of bridging therapy, as is required with the vitamin K antagonists, is not required when switching from initial treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Warfarin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of these agents and their benefits and limitations are discussed separately. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    has since been approved for the treatment of lower extremity DVT or pulmonary embolism, the earlier 2012 ACCP Guidelines had suggested the use of either a vitamin K antagonist or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    over the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    or rivaroxaban for this indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ]. With more experience using these agents, this suggestion may have to be revised. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H20#H20\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7480111\">",
"    <span class=\"h2\">",
"     Apixaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     Apixaban",
"    </a>",
"    is an orally active direct factor Xa inhibitor used for postoperative prophylaxis of VTE following elective knee or hip replacement therapy as well as stroke prevention in patients with nonvalvular atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H21#H21\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Apixaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized, double-blind study (AMPLIFY-EXT study) compared the efficacy and safety of two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    (a thromboprophylactic dose of 2.5 twice daily or a therapeutic dose of 5 mg twice daily, both given for 12 months) with those of placebo in 2482 patients with VTE who had completed 6 to 12 months of anticoagulation and for whom there was equipoise regarding the further continuation of anticoagulation. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/85\">",
"     85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic recurrent VTE or death from any cause, the primary efficacy outcome, occurred in 11.6, 3.8, and 4.2 percent of those receiving placebo, the 2.5 mg twice daily dose, and the 5 mg twice daily dose, respectively. Symptomatic recurrent VTE or VTE-related death occurred in 8.8, 1.7, and 1.7 percent, respectively.",
"     </li>",
"     <li>",
"      Non-VTE-related cardiovascular death, myocardial infarction, or stroke occurred in 1.3, 0.5, and 0.6 percent, respectively.",
"     </li>",
"     <li>",
"      Major bleeding, the primary safety outcome, occurred in 0.5, 0.2, and 0.1 percent of those receiving placebo, the 2.5 mg twice daily dose, and the 5 mg twice daily dose, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial comparing this agent with standard dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    will help to determine the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    for the continued treatment of VTE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LENGTH OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a first episode of VTE should receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy for at least three months. Attempts to decrease the treatment to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/86\">",
"     86",
"    </a>",
"    ] or six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/87\">",
"     87",
"    </a>",
"    ] have resulted in higher rates of recurrent VTE compared with either 12 or 26 weeks of therapy. In a randomized trial of almost 900 patients with a first VTE, which included patients with both idiopathic VTE and VTE due to a reversible or time-limited risk factor, the rate of recurrent thromboembolism at two years was almost twice as high with six weeks compared with six months of warfarin (18.1 versus 9.5 percent; relative risk 2.1, 95% CI 1.4-3.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Idiopathic VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without an identifiable risk factor (ie, spontaneous or idiopathic VTE) are at increased risk for a recurrent event once anticoagulation is discontinued. This was shown in a multicenter Austrian study of 826 patients with a first episode of idiopathic VTE, who were followed for an average of 36 months following cessation of treatment with oral anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/88\">",
"     88",
"    </a>",
"    ]. The incidence of recurrent VTE after the cessation of anticoagulant therapy was 12.3 percent at a median follow-up of 26 months.",
"   </p>",
"   <p>",
"    Two randomized trials showed significantly worse outcomes among patients treated for three months compared with those treated for 12 or more months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/89,90\">",
"     89,90",
"    </a>",
"    ], while two trials showed that short-term outcomes among patients treated for three months were similar to those of patients treated for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. In one of these trials, involving 267 patients with a first idiopathic DVT, recurrent VTE was significantly more likely during months 3 through 12 in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for three months compared with those receiving treatment for the entire 12-month period (8.3 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/90\">",
"     90",
"    </a>",
"    ]. However, the initial clinical benefit of longer term treatment was not maintained after warfarin was discontinued, with a recurrence rate of 5 percent per patient-year in both groups.",
"   </p>",
"   <p>",
"    Although there are published guidelines for the",
"    <strong>",
"     minimum",
"    </strong>",
"    length of time the patient with a first episode of idiopathic VTE should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    at an INR of 2.0 to 3.0 (ie, three months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/7,11,93\">",
"     7,11,93",
"    </a>",
"    ], the",
"    <strong>",
"     optimal",
"    </strong>",
"    length of time and optimal degree of anticoagulation are not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. The following examples are studies that have explored this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PREVENT trial in patients with idiopathic VTE was designed to test whether, after at least three months of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      treatment (goal INR 2.0 to 3.0), long-term lower dose warfarin (goal INR 1.5 to 2.0) was better than placebo in reducing the rate of recurrent VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/96\">",
"       96",
"      </a>",
"      ]. The study was stopped prematurely after 508 of the planned 750 patients had undergone randomization and had been followed for up to 4.3 years (mean 2.1 years), due to a significantly lower rate of recurrent VTE in the low dose warfarin treatment arm compared with placebo on an intention to treat analysis (2.6 versus 7.2 per 100 patient-years, hazard ratio [HR] 0.36, 95% CI 0.19-0.67). The increase in risk for recurrent VTE occurred throughout the follow-up period.",
"     </li>",
"     <li>",
"      The ELATE trial compared two different dose intensity levels of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (target INR 1.5 to 1.9 versus target INR 2.0 to 3.0) in 738 patients who had received three or more months of warfarin at a target INR of 2.0 to 3.0 following an episode of idiopathic VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/97\">",
"       97",
"      </a>",
"      ]. Patients were followed for an average of 2.4 years. The incidence of recurrent VTE was significantly greater in those subjects treated with the lower intensity of warfarin than with what is now the standard intensity target level of 2.0 to 3.0 (1.9 versus 0.7 per 100 patient-years, HR 2.8, 95% CI 1.1-7.0).",
"     </li>",
"     <li>",
"      The THRIVE III trial of 1233 patients with idiopathic VTE was designed to test whether, after six months of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      treatment with a goal INR of 2.0 to 3.0, 18 months of treatment with the oral direct thrombin inhibitor ximelagatran was better than placebo in reducing the rate of recurrent VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/98\">",
"       98",
"      </a>",
"      ]. The estimated cumulative risk over 18 months for recurrent VTE was significantly greater in those subjects randomly assigned to receive placebo (12.6 versus 2.8 percent, HR 6.2, 95% CI 3.3-11.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An analysis of individual participants&rsquo; data from seven such trials came to the following conclusions about length of treatment and recurrence rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrence rates were significantly lower after isolated distal DVT than after proximal DVT (HR 0.49; 95% CI 0.34-0.71), and were significantly lower after provoked VTE than after unprovoked (ie, idiopathic) VTE (HR 0.55; 95% CI 0.41-0.74).",
"     </li>",
"     <li>",
"      Recurrence rates were significantly higher if anticoagulation was stopped at one or 1.5 months compared with &ge;3 months (HR 1.52; 95% CI 1.14-2.02) and similar if treatment was stopped at three months compared with &ge;6 months (HR 1.19; 95% CI 0.86-1.65).",
"     </li>",
"     <li>",
"      High rates of recurrence associated with shorter durations of anticoagulation were confined to the first six months after stopping treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not of statistical significance, this analysis also suggested that the risk of VTE recurrence may be higher if patients with unprovoked proximal DVT or PE are treated for three months rather than six months (HR 1.57; 95% CI 0.94-2.61). However, the potential benefit of extending anticoagulation to six (or more) months may be offset by a higher risk of bleeding and the greater cost and inconvenience of the longer duration of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/7,99\">",
"     7,99",
"    </a>",
"    ]. Accordingly, the decision to continue anticoagulation for six or more, rather than three, months should be made on the basis of the patient&rsquo;s experience during the first three months of therapy as well as",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    values and preferences after being fully informed of the benefits and risks of such extended therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11754143\">",
"     'Guidance from the ISTH'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11754089\">",
"    <span class=\"h2\">",
"     Other guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no generally accepted models for estimation of the risk of thrombosis if anticoagulation is stopped after three months and none for estimating the risk of bleeding if it is continued. Recognizing this, several groups have offered guidance for patients who have suffered one or more episodes of VTE. Two of these are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11754097\">",
"    <span class=\"h3\">",
"     2012 ACCP Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 evidence-based clinical practice guidelines have acknowledged the need for guidance on this subject, emphasizing that the most important questions include estimating the risks of bleeding and thrombosis as well as the need for determining the patients&rsquo; values and preferences in regard to such risks and benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ]. They have estimated these risks as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11754105\">",
"    <span class=\"h4\">",
"     Risk of VTE recurrence after discontinuation of anticoagulation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First VTE provoked by surgery &mdash; 1 percent for the first year; 0.5",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"     <li>",
"      First VTE provoked by non-surgical factor &mdash; 5 percent for the first year; 2.5",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"     <li>",
"      First episode of unprovoked VTE &mdash; 10 percent for the first year; 5",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"     <li>",
"      Second episode of unprovoked VTE &mdash; 15 percent for the first year; 7.5",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11754120\">",
"    <span class=\"h4\">",
"     Risk of major bleeding if anticoagulation is continued",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a bleeding risk model containing a comprehensive list of 17 risk factors, the risk for major bleeding was estimated, as follows. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of warfarin\", section on 'Major risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (no risk factors present) &mdash; 1.6 percent during the first three months; 0.8",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"     <li>",
"      Intermediate risk (one risk factor present) &mdash; 3.2 percent during the first three months; 1.6",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"     <li>",
"      High risk (two or more risk factors) &mdash; 12.8 percent during the first three months; &ge;6.5",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      thereafter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Their recommendations for or against continuation of anticoagulation after an initial period of three months were based upon the perceived balance between the number of deaths from recurrent VTE prevented by continued anticoagulation versus the number of fatal bleeding episodes associated with continued anticoagulation, and are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef84025 \" href=\"mobipreview.htm?3/21/3420\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11754143\">",
"    <span class=\"h3\">",
"     Guidance from the ISTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 document from the International Society on Thrombosis and Haemostasis (ISTH) presents guidance on determining the duration of anticoagulation after the patient has received three months of anticoagulation for a first episode of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First provoked episode of VTE or unprovoked calf DVT &mdash; Suggested period of anticoagulation not to exceed three months.",
"     </li>",
"     <li>",
"      First unprovoked episode of proximal VTE &mdash; Initial treatment for three to six months, continued for as long as the perceived risk of anticoagulant-related bleeding is not so high as to preclude continued treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors, in addition to the patients&rsquo; values and preferences, which would favor continuation or discontinuation of anticoagulation following a first unprovoked episode of VTE include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       In favor of long-term anticoagulation",
"      </strong>",
"      (ie, longer than three to six months) &mdash; male gender, moderate to severe post-thrombotic syndrome, ongoing dyspnea (eg, patients with limited cardiorespiratory reserve in whom a recurrent PE may be life threatening), satisfactory initial anticoagulant control, elevated D-dimer three to four weeks after stopping anticoagulation using a study-validated assay.",
"     </li>",
"     <li>",
"      <strong>",
"       In favor of stopping anticoagulation at three to six months &mdash;",
"      </strong>",
"      female gender, absent or mild post-thrombotic syndrome, unsatisfactory initial anticoagulant control, low D-dimer result three to four weeks after stopping anticoagulation using a study-validated assay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Issues to consider",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following issues should be considered when a patient with a first idiopathic VTE has received at least three months of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    at the recommended INR of 2.0 to 3.0. The patient should be informed of the estimated incidence of VTE recurrence for the following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All anticoagulation stopped: 7.2 to 8.4 episodes per 100 patient-years in the PREVENT and THRIVE III trials) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/96,98\">",
"       96,98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Switching to treatment with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day):",
"      </span>",
"      4.8 percent per year in the ASPIRE&nbsp;study. (See",
"      <a class=\"local\" href=\"#H11015892\">",
"       'Use of aspirin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Continued therapy with lower dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (goal INR 1.5 to 2.0): 1.9 to 2.6 episodes per 100 patient-years in the ELATE and PREVENT trials) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/96,97\">",
"       96,97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Switching to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      (2.5 or 5 mg twice daily): 1.7 percent per year in the AMPLIFY-EXT study. (See",
"      <a class=\"local\" href=\"#H7480111\">",
"       'Apixaban'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continued therapy with usual dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (goal INR 2.0 to 3.0): 0.7 episodes per 100 patient-years in the ELATE trial) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding risk &mdash; The patient should also be informed of the estimated incidence of major bleeding should",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      be continued. In a large meta-analysis, the rate of major bleeding if anticoagulation was continued beyond three months was 2.7 per 100 patient-years, with a case fatality rate of 9.1 percent (95% CI 2.5-22) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H24437056#H24437056\">",
"       \"Therapeutic use of warfarin\", section on 'Use of bleeding risk scoring systems'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient values and preferences &mdash; The patient's age and comorbidities, individual bleeding risk, comfort with the difficulties of continuing anticoagulation (eg, costs, frequency of testing of the patient's INR), need for closer follow-up, and other quality of life issues should be reviewed at this time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/102-106\">",
"       102-106",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Estimation of individual risk'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As examples, for patients with a first unprovoked proximal DVT and a low or moderate risk for bleeding, the 2012 ACCP Guidelines have given a weak suggestion for extended anticoagulation rather than three months of anticoagulation, and a weak suggestion for only three months of anticoagulation in those with a high risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11754097\">",
"     '2012 ACCP Guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in all patients who receive extended treatment, the continuing use of anticoagulation should be reassessed at periodic intervals. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Length of treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     RECURRENT VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23454373\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a first unprovoked VTE event, a patient has a 5 to 15 percent risk of VTE recurrence within the first year following discontinuation of anticoagulation, and a 30 to 50 percent risk of VTE recurrence within the following 5 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/90,96,107-112\">",
"     90,96,107-112",
"    </a>",
"    ]. In two reviews and four cohort studies, clinical features most strongly associated with a high risk of VTE recurrence included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of a temporary risk factor (ie, idiopathic rather than provoked episode)",
"     </li>",
"     <li>",
"      Pulmonary embolism or proximal DVT (rather than distal DVT)",
"     </li>",
"     <li>",
"      More than two thrombotic events",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Residual vein thrombosis",
"     </li>",
"     <li>",
"      Presence of a vena cava filter",
"     </li>",
"     <li>",
"      Continued estrogen use",
"     </li>",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/114\">",
"       114",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurologic disease with paresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/115\">",
"       115",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/115,116\">",
"       115,116",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/117\">",
"       117",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Estimated glomerular filtration rate &lt;30",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/118\">",
"       118",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these risk factors were studied in a prospective follow-up of 474 patients aged 18 to 70 years with a first objectively determined episode of DVT who had received anticoagulation for a median period of four months (range: 3 to 116 months). During 3477 person-years of follow-up there were 90 recurrences, for an overall rate of recurrence of 2.59 per 100 patient-years. The overall rates of recurrence per 100 person-years were 1.58 and 4.09 for women and men, respectively. Other results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/107\">",
"     107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In women, almost half of the recurrences were provoked and were mainly related to the use of oral contraceptives or pregnancy.",
"     </li>",
"     <li>",
"      Men with an unprovoked first VTE event had the highest risk of recurrence, with almost one-third experiencing a second unprovoked event within eight years.",
"     </li>",
"     <li>",
"      Age at diagnosis and time elapsed since the first event had little effect on recurrence rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9635933\">",
"    <span class=\"h2\">",
"     Provoked versus idiopathic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the study noted above, the recurrence rate in women was similar following provoked or idiopathic first events, while the recurrence rate in men was 2.92 when the first event was provoked, and 4.38 when the first event was idiopathic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/107\">",
"     107",
"    </a>",
"    ]. The issue of recurrence risk for provoked versus unprovoked symptomatic VTE events was specifically evaluated in a systematic review of prospective cohort studies and randomized trials of patients with a first episode of symptomatic VTE provoked by a transient risk factor and treated with anticoagulation for at least three months. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/119\">",
"     119",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 24 months, the rate of recurrence was 3.3",
"      <span class=\"nowrap\">",
"       percent/patient-year",
"      </span>",
"      for all patients with a transient risk factor.",
"     </li>",
"     <li>",
"      At 24 months, the rate of recurrence was 7.4",
"      <span class=\"nowrap\">",
"       percent/patient-year",
"      </span>",
"      for all patients with an unprovoked episode of VTE.",
"     </li>",
"     <li>",
"      In a subgroup analysis, the risk of VTE recurrence at 24 months was 0.7",
"      <span class=\"nowrap\">",
"       percent/patient-year",
"      </span>",
"      when the transient risk factor was surgical, while it was 4.2",
"      <span class=\"nowrap\">",
"       percent/patient-year",
"      </span>",
"      when the transient risk factor was non-surgical (eg, immobilization, pregnancy, fracture, trauma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Length of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation for an indefinite period has been recommended for patients with recurrent venous thromboembolism as well as in those in whom there is a continuing risk factor for venous thromboembolism (eg, active malignancy, antiphospholipid syndrome). The optimum duration of therapy in such patients, as well as in those with an initial episode of unprovoked (idiopathic) VTE is still unclear, and has been the subject of both completed and ongoing clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter clinical trial evaluated the outcome of patients who received six months of oral anticoagulation compared with indefinite therapy after a",
"      <strong>",
"       second",
"      </strong>",
"      episode of VTE (19 percent with a temporary risk factor and about 20 percent with a family history of VTE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/120\">",
"       120",
"      </a>",
"      ]. Indefinite therapy (target INR 2.0 to 2.85) was associated with a significantly lower incidence of recurrent disease at four years (2.6 versus 20.7 percent in those treated for six months, relative risk 0.13, 95% CI 0.04-0.40) and a trend to a higher risk for major hemorrhage (8.6 versus 2.7 percent; relative risk 3.3 95% CI 0.9-10).",
"     </li>",
"     <li>",
"      In the PREVENT trial, patients with one or more recurrences of VTE received at least three months of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (target INR 2.0 to 3.0) and were then randomly assigned to receive either continuous treatment with a lower intensity of warfarin (target INR 1.5 to 2.0) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/96\">",
"       96",
"      </a>",
"      ]. The incidence rate for a further episode of VTE was significantly reduced in the warfarin-treated group (4.8 versus 11.4 per 100 patient-years with placebo; HR 0.43, 95% CI 0.20-0.90).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11015892\">",
"    <span class=\"h3\">",
"     Use of aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to prevent VTE recurrence in subjects with a first unprovoked VTE who had completed a course of anticoagulation was evaluated in two randomized, placebo-controlled trials. In both studies, the primary endpoint was the rate of symptomatic, objectively confirmed VTE recurrence, while the secondary endpoint was the rate of major vascular events (ie, VTE, myocardial infarction, stroke, or cardiovascular death). Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the WARFASA Study, in which all patients initially received anticoagulation for 6 to 18 months, there was a significant decrease in the primary endpoint in the 205 subjects receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (6.6",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      as compared with the 197 subjects receiving placebo (11.2",
"      <span class=\"nowrap\">",
"       percent/year;",
"      </span>",
"      HR 0.58; 95% CI 0.36-0.93) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/121\">",
"       121",
"      </a>",
"      ]. The rate of the secondary endpoint was reduced in the aspirin-treated group, although this did not reach statistical significance (HR 0.67; 95% CI 0.43-1.03). Bleeding rates were similar in the two treatment arms (0.3",
"      <span class=\"nowrap\">",
"       percent/patient-year).",
"      </span>",
"     </li>",
"     <li>",
"      In the ASPIRE Study, in which approximately two-thirds of the patients received anticoagulation for 6 to 12 months, there was a decrease in the primary endpoint over the subsequent four years in the 411 subjects receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (4.8",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      as compared with the 411 subjects receiving placebo (6.5",
"      <span class=\"nowrap\">",
"       percent/year),",
"      </span>",
"      although this did not reach statistical significance (HR 0.74; 95% CI 0.52-1.05) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/122\">",
"       122",
"      </a>",
"      ]. The rate of the secondary endpoint was significantly reduced in the aspirin treated group (5.2 versus 8.0",
"      <span class=\"nowrap\">",
"       percent/year;",
"      </span>",
"      HR 0.67; 95% CI 0.49-0.91). The rates of bleeding and serious adverse events were similar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospectively planned combined analysis of the WARFASA and ASPIRE trials indicated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as compared with placebo, significantly reduced the rate of VTE recurrence by 32 percent (HR 0.68; 95% CI 0.51-0.90) and the rate of major vascular events by 34 percent (HR 0.66; 95% CI 0.51-0.86), with no excess of bleeding.",
"   </p>",
"   <p>",
"    This combined analysis indicates that switching to treatment with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as compared with cessation of anticoagulation, significantly reduces by approximately one-third the risks of recurrent VTE and arterial cardiovascular events in patients with unprovoked VTE who have received 6 to 18 months of effective anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/123\">",
"     123",
"    </a>",
"    ]. While this analysis does not directly answer the question of whether switching to aspirin is safer and more effective than continuation of anticoagulation, comparison with available studies suggests that low-dose aspirin is less effective (ie, higher recurrence rate) but safer (ie, lower bleeding rate) than continuation of anticoagulation. (See",
"    <a class=\"local\" href=\"#H11754097\">",
"     '2012 ACCP Guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The decision as to whether or not to continue anticoagulation, switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or to discontinue anticoagulation depends upon a number of factors, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      reduces the risk of VTE recurrence by approximately one-third, while continuation of anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      reduces this risk by approximately 90 percent.",
"     </li>",
"     <li>",
"      The patient&rsquo;s past ability to be well-controlled on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (eg, high percentage of time in effective INR range, lack of bleeding and other side effects, patient comfort with need for INR testing).",
"     </li>",
"     <li>",
"      The estimated risk of the patient for VTE recurrence. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Estimation of individual risk'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H11754105\">",
"       'Risk of VTE recurrence after discontinuation of anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated risk of the patient for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      - and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -associated bleeding. (See",
"      <a class=\"local\" href=\"#H11754120\">",
"       'Risk of major bleeding if anticoagulation is continued'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"       \"Therapeutic use of warfarin\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other",
"      <span class=\"nowrap\">",
"       patient/clinician",
"      </span>",
"      preferences, such as switching to an anticoagulant that does not require monitoring (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26119476\">",
"    <span class=\"h2\">",
"     Site of initial involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The site of the initial episode of VTE appears to influence the rate of recurrence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 1149 consecutive patients with symptomatic proximal DVT treated with conventional anticoagulation, the rate of recurrence during the initial three months of treatment was 5.1, 5.3, and 11.8 percent for those with popliteal, femoral, or iliofemoral vein thrombosis, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/124\">",
"       124",
"      </a>",
"      ]. Multivariate regression analysis indicated a trend to higher rates of recurrence in patients with iliofemoral vein thrombosis versus the two other sites (odds ratio 2.4, 95% CI 0.95-5.9).",
"     </li>",
"     <li>",
"      In a study of 646 patients with a first episode of symptomatic unprovoked VTE who were treated with conventional anticoagulation for five to seven months, there were 91 recurrent VTE events during a mean of 18 months of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/125\">",
"       125",
"      </a>",
"      ]. The crude recurrent VTE rate for those whose initial events were isolated PE, isolated DVT, or combined PE and DVT were 7.7, 16.5, and 17.7 percent, respectively. The relative risk of recurrent VTE for isolated DVT versus isolated PE was 2.1 (95% CI 1.2-3.7).",
"     </li>",
"     <li>",
"      In a patient-level meta-analysis of seven prospective studies in patients with a first episode of VTE who were followed after anticoagulation was stopped, the risk of recurrence as PE was 3.1-fold greater in those initially presenting with symptomatic PE than in those presenting with proximal DVT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/109\">",
"       109",
"      </a>",
"      ]. Subjects presenting with proximal DVT had a 4.8-fold higher cumulative recurrence rate than those presenting with distal DVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Estimation of individual risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial interpatient variability in the risk of recurrent DVT following cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy after an initial episode of idiopathic VTE. Measurement of D-dimer levels, serial imaging, and measurement of thrombin generation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/126,127\">",
"     126,127",
"    </a>",
"    ] may be helpful in determining this risk, although prediction of recurrence in an individual patient remains a challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/113,128\">",
"     113,128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     D-dimer levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports and three meta-analyses suggest that D-dimer levels can be used to predict the risk of VTE recurrence during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/129,130\">",
"     129,130",
"    </a>",
"    ] or after withdrawal of oral anticoagulants used to treat a first episode of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/131-139\">",
"     131-139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one meta-analysis of seven studies, the annualized risk of VTE recurrence was significantly higher in subjects with abnormal (8.9 percent; 95% CI 5.8-12) versus normal (3.5 percent; 95% CI 2.7-4.3) D-dimer following at least three months of anticoagulation therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second meta-analysis was confined to studies of patients with idiopathic VTE who had levels of D-dimer measured one month after discontinuation of oral anticoagulants. Elevated D-dimer levels obtained at this time were significantly associated with recurrent VTE (odds ratio 2.36; 95% CI 1.65-3.36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third meta-analysis concluded that the timing of D-dimer testing following cessation of anticoagulation (eg, &lt;3 weeks, three to five weeks, &gt;5 weeks), patient age, and the D-dimer assay cut point used did not reduce the ability of this test to distinguish patients with a higher or lower risk for recurrent VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PROLONG II prospective cohort study addressed the natural history of D-dimer levels after withdrawal of anticoagulation therapy (AC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/140\">",
"     140",
"    </a>",
"    ]. Subjects with a first episode of unprovoked VTE and a normal level of D-dimer at one month following discontinuation of AC were followed with serial D-dimer studies every two months for one year. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/141\">",
"     141",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the initial 355 enrolled subjects, 336 had normal levels of D-dimer on the last day of AC and 328 had normal D-dimer levels at 30 days following discontinuation of AC. Those with abnormal levels at either day zero or day 30 continued or resumed AC.",
"     </li>",
"     <li>",
"      Subjects in whom the D-dimer became abnormal at the third month and remained abnormal afterward had a significantly higher risk of recurrent VTE (7 of 31, 27 per 100 patient-years) than those whose D-dimer remained normal at three months and thereafter (4 of 149, 2.9 per 100 patient-years; hazard ratio 7.9; 95% CI 2.1-30).",
"     </li>",
"     <li>",
"      Patients in whom the D-dimer was normal at the third month but became abnormal thereafter had an intermediate risk of recurrent VTE (5 of 46, 11.1 per 100 patient-years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The follow-up DULCIS study will test D-dimer levels and evaluate for residual vein obstruction (RVO) at 30 days after cessation of AC. Subjects with repeatedly normal D-dimer levels more than three months after withdrawal of AC and without significant RVO will not resume AC, while those in whom the D-dimer becomes abnormal over the first three months after stopping AC will resume treatment. Results of this study were expected to be available by the end of 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Serial imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have examined the predictive value of serial invasive (eg, venography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/143\">",
"     143",
"    </a>",
"    ] or noninvasive (eg, impedance plethysmography or ultrasound) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/144-149\">",
"     144-149",
"    </a>",
"    ] studies for predicting VTE recurrence after the cessation of oral anticoagulation (OAT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2011 review of 11 randomized studies concluded that the presence of residual vein obstruction (RVO) at the time of cessation of OAT is a risk factor for VTE recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/150\">",
"       150",
"      </a>",
"      ]. The effect was more pronounced in patients with malignancy and was dependent upon the criteria used to measure residual thrombosis.",
"     </li>",
"     <li>",
"      A separate 2011 review of nine prospective cohort studies and five randomized controlled trials concluded that RVO did not seem to be a predictor of recurrent VTE in patients with unprovoked VTE following anticoagulation discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/151\">",
"       151",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 296 consecutive patients with a first episode of symptomatic provoked DVT, RVO as determined by compression ultrasonography was present in 45 percent at the time of cessation of oral anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/152\">",
"       152",
"      </a>",
"      ]. However, RVO was not significantly associated with VTE recurrence, and RVO did not increase the recurrence risk associated with an abnormal D-dimer either at the time of cessation of anticoagulation, or at 30 days after cessation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two of these studies indicated significant heterogeneity due to differences in study population, timing, and differences in the RVO definitions used in the included studies. It has been concluded that, given the available data, there is little clinical value in assessing RVO, which should not be part of standard clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of imaging after completion of anticoagulant therapy for unprovoked VTE for the purpose of aiding the interpretation of diagnostic testing in those who",
"    <strong>",
"     subsequently",
"    </strong>",
"    have suspected recurrent VTE is under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Thrombin generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 254 patients with a first episode of unprovoked, objectively documented VTE who were followed for 2.7 years after discontinuation of vitamin K antagonists, those with higher values for thrombin generation measured one month after discontinuation of treatment had hazard ratios for VTE recurrence that were 3.0 to 6.3-fold higher than those with lesser values of thrombin generation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/155,156\">",
"     155,156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A larger study involving 914 selected patients with a first episode of spontaneous idiopathic VTE, who were treated with oral anticoagulants for a minimum of three months, also investigated the association between VTE recurrence and in vitro thrombin generation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/157\">",
"     157",
"    </a>",
"    ]. After four years, the cumulative probability of objectively documented VTE recurrence was 20 and 6.5 percent for those whose thrombin generation, determined at a median of 13 months following cessation of anticoagulation, was greater than versus less than 400 nM, respectively (relative risk 2.50 (95% CI 1.7-3.7) for those with the higher values of thrombin generation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Increased risk in men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Austrian, THRIVE III trials, Cambridge and Leiden studies, and a meta-analysis of 15 studies, the risk of recurrent VTE after cessation of oral anticoagulant therapy was significantly increased among men, with relative risks varying from 1.3 to 3.6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/88,98,158-161\">",
"     88,98,158-161",
"    </a>",
"    ]. A trend toward increased risk of recurrence in men was noted in the PREVENT trial (8.6 versus 5.9 percent per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/96\">",
"     96",
"    </a>",
"    ], but no sex difference was noted in two Italian studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for this apparent difference in the rate of recurrence in some studies are not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/163,164\">",
"     163,164",
"    </a>",
"    ]. However, in two studies, the rates of recurrent thrombosis in men and women were similar when women with hormone-related thrombosis (eg, treatment with exogenous hormones, pregnancy, post-partum status) were removed from the analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/165,166\">",
"     165,166",
"    </a>",
"    ]. Hormone-related factors also appear to be related to a reduced risk of recurrent venous thrombosis in women from thrombophilic families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Risk in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter prospective cohort study of 646 participants with a first, unprovoked episode of major VTE collected data on 69 potential predictors for recurrent VTE while patients were still taking oral anticoagulants for five to seven months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/130\">",
"     130",
"    </a>",
"    ]. The overall annual risk of recurrence was 9.3 percent, and was 5.5 versus 13.7 percent for women and men, respectively. There was no combination of clinical predictors that satisfied criteria for identifying a low-risk subgroup in men. However, the following characteristics helped to define a low-risk as well as a high-risk group in women:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperpigmentation, edema, or redness of either leg",
"     </li>",
"     <li>",
"      D-dimer &ge;250",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      while still taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"     </li>",
"     <li>",
"      Body mass index &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Age &ge;65 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with zero or one of these adverse risk factors had an annual risk of VTE recurrence of 1.6 percent (95% CI 0.3-4.6), while those with two or more had an annual risk of 14.1 percent (95% CI 10.9-17.3).",
"   </p>",
"   <p>",
"    A retrospective subgroup analysis of the PROLONG study, in which patients with a normal D-dimer one month after discontinuation of anticoagulation did not resume anticoagulation, evaluated the effects of sex and age on VTE recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/166\">",
"     166",
"    </a>",
"    ]. Recurrence rates were lowest for women &lt;65 (0.4 per 100 patient-years), whereas rates in women &gt;65 (6.7 per 100 patient-years) were similar to those in men &lt;65 or &gt;65 (5.1 and 8.2 per 100 patient-years, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above-noted approaches for preventing recurrent VTE (ie, fixed length of treatment versus individualized treatment) need to be confirmed in larger studies before they can be routinely employed in the decision concerning the risk of recurrence for an individual patient and whether (as well as when) treatment with anticoagulation can be safely discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/168-170\">",
"     168-170",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic literature review of this subject has concluded that none of the factors discussed above is strong enough on its own to guide length of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/171\">",
"     171",
"    </a>",
"    ]. One suggested approach has been the use of risk assessment models (eg, the Vienna prediction model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/172\">",
"     172",
"    </a>",
"    ], the DASH prediction rule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/173\">",
"     173",
"    </a>",
"    ]), which take into account patient sex and age, location of the initial event (ie, distal DVT, proximal DVT, or PE), D-dimer level, and use of hormone therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute DVT in the pregnant woman should be managed initially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in an identical fashion as when DVT occurs in the nonpregnant patient.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    freely crosses the placental barrier and can produce an embryopathy when given between the sixth and ninth weeks of pregnancy. For this reason, either subcutaneous unfractionated or LMW heparin (which should be switched to unfractionated heparin two weeks prior to the expected delivery) at full doses should be continued until delivery; a four- to six-week course of warfarin should be completed after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15994522\">",
"    <span class=\"h2\">",
"     General medical management and ambulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small randomized studies and a systematic review have shown that early ambulation with or without the use of leg compression does not increase the incidence of silent, recurrent, or fatal pulmonary emboli and, in one study, resulted in a significantly faster rate of resolution of pain and swelling when compared with bed rest alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/43,44,177-183\">",
"     43,44,177-183",
"    </a>",
"    ]. The use of elastic graduated compression stockings has been found to be valuable in order to prevent post-thrombotic (postphlebitic) syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/33,177,184,185\">",
"     33,177,184,185",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23127?source=see_link&amp;anchor=H436298802#H436298802\">",
"     \"Post-thrombotic (postphlebitic) syndrome\", section on 'Compression therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies that address the timing of aggressive exercise or physical therapy rehabilitation for patients recovering from VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/182\">",
"     182",
"    </a>",
"    ]. In this setting, the clinical status of the patient (eg, cardiopulmonary reserve, presence or absence of vascular compromise of the lower extremity), as well as the clinical judgment of the treating clinician, are critical for devising an appropriate rehabilitation program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15994263\">",
"    <span class=\"h1\">",
"     ISOLATED CALF VEIN (DISTAL, BELOW THE KNEE) THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies that offer guidance on the appropriate treatment of patients with isolated calf vein (ie, distal) deep vein thrombosis. A meta-analysis that included two randomized and six non-randomized cohort studies dealing with anticoagulation for calf vein thrombosis indicated that the methodologic quality of most studies was poor, with only a small number of events (ie, deaths, pulmonary emboli, proximal DVT extension, bleeding) available for analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/186\">",
"     186",
"    </a>",
"    ]. The only robust conclusion of the meta-analysis was that proximal thrombus propagation was significantly less frequent in those receiving anticoagulation (OR 0.29; 95% CI 0.14-0.62).",
"   </p>",
"   <p>",
"    Factors favoring the use of anticoagulation for isolated distal DVT include the severity of symptoms, as well as the perceived risk of proximal extension (eg, positive D-dimer, extensive thrombosis or thrombosis close to the proximal veins, active cancer, prior VTE, and inpatient status) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If anticoagulation is to be employed for treatment of symptomatic calf vein thrombosis, suggested lengths of treatment have ranged from six weeks to three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3,87,91,177,187-189\">",
"       3,87,91,177,187-189",
"      </a>",
"      ]. We and others suggest that three months of treatment will minimize the risk of proximal extension most effectively, although the evidence in favor of this length of time is of poor quality.",
"     </li>",
"     <li>",
"      If anticoagulation is not administered (eg, isolated asymptomatic distal DVT), serial noninvasive studies of the lower extremity should be performed over the next 10 to 14 days to assess for proximal extension of the thrombus, which is most likely to occur during this two-week period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/190-192\">",
"       190-192",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The natural history of isolated symptomatic thrombosis involving the deep veins draining the gastrocnemius and soleus muscles in the calf (",
"      <a class=\"graphic graphic_table graphicRef77469 \" href=\"mobipreview.htm?24/54/25451\">",
"       table 8",
"      </a>",
"      ) is unclear, and guidelines for the treatment of this condition do not exist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/188,193-198\">",
"       188,193-198",
"      </a>",
"      ]. However, thrombosis confined to the muscular veins appears to have a lower risk of extension than true isolated distal DVT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3,194,197\">",
"       3,194,197",
"      </a>",
"      ]. Available studies do not suggest that anticoagulation is superior to either no therapy or use of compression therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/197,198\">",
"       197,198",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations for the treatment of acute venous thromboembolic disease are in general accord with recommendations from the following sources: the 2008 and 2012 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3,177\">",
"     3,177",
"    </a>",
"    ], the 2012 guidance document from the International Society on Thrombosis and Haemostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/100\">",
"     100",
"    </a>",
"    ], the British Committee for Standards in Haematology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/199\">",
"     199",
"    </a>",
"    ], the joint guidelines of the American College of Physicians and the American Academy of Family Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/184,200\">",
"     184,200",
"    </a>",
"    ], and the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/4/43082/abstract/201\">",
"     201",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Initial anticoagulation regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients with proximal DVT be treated acutely with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , unfractionated intravenous heparin, adjusted-dose or fixed dose subcutaneous heparin, or subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    &nbsp;(",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). In comparison to unfractionated heparin, LMW heparin and fondaparinux offer the major benefits of convenient dosing, facilitation of outpatient treatment, and a lower incidence of heparin-induced thrombocytopenia. If direct cost to the patient is not an issue, we recommend that clinicians use LMW heparin over unfractionated heparin (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Low molecular weight heparin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dosing requirements for LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      are individualized for each product. Minimal elements for early discharge or outpatient therapy using these agents are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef70140 \" href=\"mobipreview.htm?16/35/16955\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The dosing of LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in special patient groups (eg, the elderly, obesity, renal failure) is discussed separately. In patients with severe renal failure (eg, creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      we suggest intravenous unfractionated heparin over LMW heparin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H35#H35\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Special patient groups'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is used, we recommend that the dose should be sufficient to prolong the aPTT to a range that corresponds to a plasma heparin level of 0.3 to 0.7",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      by an anti-Xa assay (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Unfractionated heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that treatment with LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , heparin, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      should be continued for at least five days and that oral anticoagulation with a vitamin K antagonist be initiated simultaneously and both agents overlapped for at least five days (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The heparin or fondaparinux can be discontinued on day 5 or 6 if the INR has been in the therapeutic range for at least 24 hours or two consecutive days.",
"     </li>",
"     <li>",
"      To monitor for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia, platelet counts should be regularly obtained. The timing and frequency of such testing differs with the clinical setting, and is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H11#H11\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Platelet count monitoring'",
"      </a>",
"      .) All heparin products should be stopped if any one of the following occurs: a precipitous or sustained fall in the platelet count, or a platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of thrombolytic agents in the treatment of venous thromboembolism must be individualized and requires further investigation. Patients with hemodynamically unstable PE or massive iliofemoral thrombosis, and who are also at low risk to bleed, are the most appropriate candidates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link\">",
"       \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The placement of an inferior vena cava filter is recommended when there is a contraindication to, or a failure of, anticoagulant therapy in an individual with acute proximal vein DVT (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Inferior vena cava filter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As an integral part of the initial treatment of VTE, we recommend that oral anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      should prolong the INR to a target of 2.5 (INR range: 2.0 to 3.0) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend against high-intensity therapy (INR range: 3.1 to 4.0) as well as against low-intensity therapy (INR range: 1.5 to 1.9), compared with an INR range of 2.0 to 3.0 (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the use of vitamin K antagonists is contraindicated or inconvenient, long-term therapy can be undertaken with either low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or adjusted-dose unfractionated heparin. Other orally-active anticoagulants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) have been studied in this setting, although issues concerning FDA approval, long-term safety, drug-drug interactions, and their use in older patients and those with hepatic or renal disease need to be clarified before these agents can be recommended for use in this setting. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Dabigatran and rivaroxaban'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H20#H20\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Rivaroxaban'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7480111\">",
"     'Apixaban'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general medical management of the acute attack of DVT is individualized. Once",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"      warfarin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"    </span>",
"    have been started, the patient is hemodynamically stable, and symptoms (eg, pain, swelling) are under control, we recommend early ambulation in preference to bed rest (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During initial ambulation, and for the first two years following an episode of VTE, we recommend use of an elastic graduated compression stocking with a pressure of 30 to 40 mmHg at the ankle (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). This recommendation places a higher priority on prevention of post-thrombotic syndrome than on the discomfort attendant to their use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23127?source=see_link&amp;anchor=H436298802#H436298802\">",
"     \"Post-thrombotic (postphlebitic) syndrome\", section on 'Compression therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     VTE and a reversible or time-limited risk factor",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with a first thromboembolic event in the context of a reversible or time-limited risk factor (ie, provoked VTE such as from surgery, trauma, pregnancy, use of oral contraceptives) be treated for three months, rather than for a shorter or longer period of time (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Length of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In those patients with a continuing risk factor that is potentially reversible (eg, prolonged immobilization), long-term therapy should be continued until the risk factor is reversed. Patients with multiple episodes of provoked VTE are generally not offered long-term anticoagulation, but are strongly advised to undergo prophylactic anticoagulation when they are at high risk for VTE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     First episode of idiopathic VTE",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a patient with a first episode of idiopathic (unprovoked) proximal DVT, we recommend anticoagulation for three to six months, rather than for a shorter period of time (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest indefinite treatment (eg, &gt;12 months) over treatment for three to six months for those with a low bleeding risk (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with a moderate or high bleeding risk the benefits of indefinite anticoagulation are less certain, and depend heavily on patient-specific bleeding and thrombotic risks as well as the patient&rsquo;s values and preferences. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Issues to consider'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following the initial three to six months of anticoagulation, and periodically thereafter, all patients should be evaluated for the",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratios of continuation of anticoagulation, discontinuation of anticoagulation, or the use of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Patient values and preferences, the ability to achieve good anticoagulation monitoring, and the estimated risk of bleeding and VTE recurrence for that patient will factor heavily into this decision. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Length of treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11015892\">",
"       'Use of aspirin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Estimation of individual risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Recurrent VTE and antiphospholipid syndrome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a low bleeding risk and either a second episode of unprovoked VTE or the antiphospholipid syndrome and VTE, we recommend indefinite anticoagulation over three months of anticoagulation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of the antiphospholipid syndrome\", section on 'Duration of warfarin use'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a moderate or high bleeding risk and either a second episode of unprovoked VTE or the antiphospholipid syndrome and VTE, the benefits of indefinite anticoagulation are less certain, and depend heavily on patient-specific risks as well as the patient&rsquo;s values and preferences. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Recurrent VTE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Distal (calf vein) thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"local\" href=\"#H15994263\">",
"     'Isolated calf vein (distal, below the knee) thrombosis'",
"    </a>",
"    above)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with",
"      <strong>",
"       unprovoked",
"      </strong>",
"      symptomatic isolated calf vein (ie, distal or below the knee) thrombosis, we suggest anticoagulation for three months, rather than indefinite therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Calf vein thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are few studies that offer guidance on the appropriate length of treatment of patients with",
"      <strong>",
"       provoked",
"      </strong>",
"      symptomatic isolated calf vein (ie, distal) thrombosis. If anticoagulation is not administered, serial noninvasive studies of the lower extremity should be performed over the next 10 to 14 days to assess for proximal extension of the thrombus.",
"     </li>",
"     <li>",
"      Guidelines for the treatment of isolated symptomatic thrombosis involving the deep veins draining the gastrocnemius and soleus muscles in the calf do not exist. Available studies do not suggest that anticoagulation is superior to either no therapy or use of compression therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7994132\">",
"    <span class=\"h2\">",
"     Contraindication to anticoagulation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with an acute proximal DVT and a contraindication to the use of anticoagulation (eg, active bleeding), we recommend insertion of a vena cava filter (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Inferior vena cava filter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For such patients we suggest a conventional course of anticoagulation if the risk of bleeding resolves (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with malignancy and VTE is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticoagulation for VTE in patients with primary or secondary brain tumors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Anticoagulation failure and massive iliofemoral thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, patients may have VTE that does not respond to, or recurs after, adequate anticoagulation. The recourses for such patients include increasing the anticoagulant dosage, switching to an alternative anticoagulant, insertion of an inferior vena cava filter, or one or more vascular interventions such as thrombolytic therapy or thrombectomy.",
"   </p>",
"   <p>",
"    A vascular surgery or interventional radiology consultation should be obtained under such circumstances. This is especially critical for those with impending gangrene, as in phlegmasia cerulea dolens (acute massive iliofemoral thrombosis). The selected intervention(s) will depend upon available expertise. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Thrombolytic therapy and thrombectomy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Inferior vena cava filter'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/1\">",
"      Galanaud JP, Sevestre-Pietri MA, Bosson JL, et al. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 2009; 102:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/2\">",
"      Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ 2002; 325:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/3\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/4\">",
"      Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/5\">",
"      Mannucci PM, Poller L. Venous thrombosis and anticoagulant therapy. Br J Haematol 2001; 114:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/6\">",
"      BARRITT DW, JORDAN SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/7\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/8\">",
"      Hirsh J, Bates SM. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med 2001; 134:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/9\">",
"      Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/10\">",
"      Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/11\">",
"      Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/12\">",
"      Colvin BT, Barrowcliffe TW. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1993; 46:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/13\">",
"      Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/14\">",
"      Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/15\">",
"      Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/16\">",
"      Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a \"standard care\" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/17\">",
"      Brandjes DP, Heijboer H, B&uuml;ller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/18\">",
"      Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997; 157:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/19\">",
"      Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/20\">",
"      Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/21\">",
"      Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/22\">",
"      Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/23\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/24\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/25\">",
"      Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/26\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/27\">",
"      Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. Br Med J (Clin Res Ed) 1985; 290:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/28\">",
"      Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/29\">",
"      Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/30\">",
"      Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003; 163:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/31\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/32\">",
"      Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/33\">",
"      Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/34\">",
"      Kakkar VV, Hoppenstead DA, Fareed J, et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/35\">",
"      Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/36\">",
"      Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/37\">",
"      Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/38\">",
"      Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/39\">",
"      Breddin HK, Hach-Wunderle V, Nakov R, et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/40\">",
"      Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/41\">",
"      Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost 2001; 86:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/42\">",
"      Douketis JD. Treatment of deep vein thrombosis: what factors determine appropriate treatment? Can Fam Physician 2005; 51:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/43\">",
"      Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/44\">",
"      Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/45\">",
"      Boccalon H, Elias A, Chal&eacute; JJ, et al. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med 2000; 160:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/46\">",
"      O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM 2000; 93:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/47\">",
"      Grau E, Tenias JM, Real E, et al. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 2001; 67:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/48\">",
"      Dunn A, Bioh D, Beran M, et al. Effect of intravenous heparin administration on duration of hospitalization. Mayo Clin Proc 2004; 79:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/49\">",
"      Dunn AS, Schechter C, Gotlin A, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001; 110:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/50\">",
"      Segal JB, Bolger DT, Jenckes MW, et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med 2003; 115:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/51\">",
"      Othieno R, Abu Affan M, Okpo E. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2007; :CD003076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/52\">",
"      Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/53\">",
"      Daskalopoulos ME, Daskalopoulou SS, Liapis CD. Tinzaparin in long-term treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2007; 34:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/54\">",
"      Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009; 122:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/55\">",
"      Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/56\">",
"      Andras A, Sala Tenna A, Crawford F. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2012; 10:CD002001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/57\">",
"      Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997; 157:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/58\">",
"      Rodger M, Bredeson C, Wells PS, et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998; 159:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/59\">",
"      Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/60\">",
"      O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999; 159:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/61\">",
"      de Lissovoy G, Yusen RD, Spiro TE, et al. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Arch Intern Med 2000; 160:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/62\">",
"      Lensing AW, Prandoni P, Prins MH, B&uuml;ller HR. Deep-vein thrombosis. Lancet 1999; 353:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/63\">",
"      Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2012; 55:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/64\">",
"      Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984; 76:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/65\">",
"      Rogers LQ, Lutcher CL. Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. Am J Med 1990; 88:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/66\">",
"      Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/67\">",
"      Turpie AG, Levine MN, Hirsh J, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest 1990; 97:172S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/68\">",
"      Grewal NK, Martinez JT, Andrews L, Comerota AJ. Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity. J Vasc Surg 2010; 51:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/69\">",
"      Vedantham S. Interventional approaches to deep vein thrombosis. Am J Hematol 2012; 87 Suppl 1:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/70\">",
"      Markel A, Manzo RA, Strandness DE Jr. The potential role of thrombolytic therapy in venous thrombosis. Arch Intern Med 1992; 152:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/71\">",
"      O'Meara JJ 3rd, McNutt RA, Evans AT, et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/72\">",
"      Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/73\">",
"      Tung CS, Soliman PT, Wallace MJ, et al. Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. Gynecol Oncol 2007; 107:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/74\">",
"      Oguzkurt L, Tercan F, Ozkan U. Manual aspiration thrombectomy with stent placement: rapid and effective treatment for phlegmasia cerulea dolens with impending venous gangrene. Cardiovasc Intervent Radiol 2008; 31:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/75\">",
"      Vedantham S. Interventional approaches to acute venous thromboembolism. Semin Respir Crit Care Med 2008; 29:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/76\">",
"      Casey ET, Murad MH, Zumaeta-Garcia M, et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/77\">",
"      Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/78\">",
"      Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/79\">",
"      Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/80\">",
"      Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/81\">",
"      Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012; 157:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/82\">",
"      EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/83\">",
"      EINSTEIN&ndash;PE Investigators, B&uuml;ller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/84\">",
"      Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012; 345:e7498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/85\">",
"      Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/86\">",
"      Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/87\">",
"      Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/88\">",
"      Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/89\">",
"      Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/90\">",
"      Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/91\">",
"      Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/92\">",
"      Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/93\">",
"      Schafer AI. Warfarin for venous thromboembolism - walking the dosing tightrope. N Engl J Med 2003; 348:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/94\">",
"      Kearon C. Duration of therapy for acute venous thromboembolism. Clin Chest Med 2003; 24:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/95\">",
"      Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005; 294:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/96\">",
"      Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/97\">",
"      Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/98\">",
"      Schulman S, W&aring;hlander K, Lundstr&ouml;m T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/99\">",
"      Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342:d3036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/100\">",
"      Baglin T, Bauer K, Douketis J, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 2012; 10:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/101\">",
"      Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/102\">",
"      van Korlaar I, Vossen C, Rosendaal F, et al. Quality of life in venous disease. Thromb Haemost 2003; 90:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/103\">",
"      Bauer KA. Low intensity warfarin: is it clinically useful in venous thromboembolism management? Br J Haematol 2004; 127:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/104\">",
"      Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost 2004; 92:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/105\">",
"      Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 2005; 118:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/106\">",
"      de Jong PG, Coppens M, Middeldorp S. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term. Br J Haematol 2012; 158:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/107\">",
"      Christiansen SC, Lijfering WM, Helmerhorst FM, et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 2010; 8:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/108\">",
"      Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 2010; 8:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/109\">",
"      Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/110\">",
"      Schulman S, Lindmarker P, Holmstr&ouml;m M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/111\">",
"      Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/112\">",
"      Prandoni P, Hutten BA, van Dongen CJ, et al. Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis. J Thromb Haemost 2007; 5:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/113\">",
"      Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/114\">",
"      Piazza G, Goldhaber SZ, Kroll A, et al. Venous thromboembolism in patients with diabetes mellitus. Am J Med 2012; 125:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/115\">",
"      Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/116\">",
"      Heit JA, Lahr BD, Petterson TM, et al. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011; 118:4992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/117\">",
"      Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/118\">",
"      Parikh AM, Spencer FA, Lessard D, et al. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis 2011; 58:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/119\">",
"      Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/120\">",
"      Schulman S, Granqvist S, Holmstr&ouml;m M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/121\">",
"      Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/122\">",
"      Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/123\">",
"      Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/124\">",
"      Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 2001; 110:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/125\">",
"      Kovacs MJ, Kahn SR, Wells PS, et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J Thromb Haemost 2010; 8:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/126\">",
"      Gatt A, van Veen JJ, Bowyer A, et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. Br J Haematol 2008; 142:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/127\">",
"      van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/128\">",
"      Goldhaber SZ, Piazza G. Optimal duration of anticoagulation after venous thromboembolism. Circulation 2011; 123:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/129\">",
"      Kuruvilla J, Wells PS, Morrow B, et al. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost 2003; 89:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/130\">",
"      Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/131\">",
"      K&eacute;vorkian JP, Halimi C, Segrestaa JM, et al. Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D-dimer. Lancet 1998; 351:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/132\">",
"      Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/133\">",
"      Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/134\">",
"      Shrivastava S, Ridker PM, Glynn RJ, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 2006; 4:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/135\">",
"      Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/136\">",
"      Poli D, Antonucci E, Ciuti G, et al. Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost 2008; 6:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/137\">",
"      Bruinstroop E, Klok FA, Van De Ree MA, et al. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009; 7:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/138\">",
"      Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/139\">",
"      Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010; 153:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/140\">",
"      Pernod G, Sevestre MA, Labarere J. D-dimer and duration of anticoagulation. N Engl J Med 2007; 356:421; author reply 423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/141\">",
"      Cosmi B, Legnani C, Tosetto A, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 2010; 115:481.",
"     </a>",
"    </li>",
"    <li>",
"     Trial number NCT00954395. Details available at file://clinical trials.gov (Accessed on January 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/143\">",
"      Hull RD, Marder VJ, Mah AF, et al. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med 2005; 118:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/144\">",
"      Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/145\">",
"      Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/146\">",
"      Young L, Ockelford P, Milne D, et al. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/147\">",
"      Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008; 112:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/148\">",
"      Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/149\">",
"      LE Gal G, Carrier M, Kovacs MJ, et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J Thromb Haemost 2011; 9:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/150\">",
"      Tan M, Mos IC, Klok FA, Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br J Haematol 2011; 153:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/151\">",
"      Carrier M, Rodger MA, Wells PS, et al. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2011; 9:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/152\">",
"      Cosmi B, Legnani C, Cini M, et al. D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. Thromb Haemost 2011; 105:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/153\">",
"      Watson HG. RVO--real value obscure. J Thromb Haemost 2011; 9:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/154\">",
"      Hamadah A, Alwasaidi T, LE Gal G, et al. Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence. J Thromb Haemost 2011; 9:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/155\">",
"      Tripodi A, Legnani C, Chantarangkul V, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/156\">",
"      Tripodi A, Legnani C, Palareti G, et al. More on: high thrombin generation and the risk of recurrent venous thromboembolism. J Thromb Haemost 2009; 7:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/157\">",
"      Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/158\">",
"      Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004; 2:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/159\">",
"      Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/160\">",
"      McRae S, Tran H, Schulman S, et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/161\">",
"      Baglin T, Palmer CR, Luddington R, Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost 2008; 6:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/162\">",
"      Agnelli G, Becattini C, Prandoni P. Recurrent venous thromboembolism in men and women. N Engl J Med 2004; 351:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/163\">",
"      Elliott CG, Rubin LJ. Mars or venus--is sex a risk factor for recurrent venous thromboembolism? N Engl J Med 2004; 350:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/164\">",
"      Pengo V, Prandoni P. Sex and anticoagulation in patients with idiopathic venous thromboembolism. Lancet 2006; 368:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/165\">",
"      Cushman M, Glynn RJ, Goldhaber SZ, et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost 2006; 4:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/166\">",
"      Cosmi B, Legnani C, Tosetto A, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost 2010; 8:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/167\">",
"      Lijfering WM, Veeger NJ, Middeldorp S, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 2009; 114:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/168\">",
"      Siragusa S, Caramazza D, Malato A. How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs? Br J Haematol 2009; 144:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/169\">",
"      Goldhaber SZ. Optimal duration of anticoagulation after venous thromboembolism: fixed and evidence-based, or flexible and personalized? Ann Intern Med 2009; 150:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/170\">",
"      Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012; 87 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/171\">",
"      Meijer K, Schulman S. The absence of 'minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios. J Thromb Haemost 2009; 7:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/172\">",
"      Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/173\">",
"      Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/174\">",
"      Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012; 108:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/175\">",
"      Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:844S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/176\">",
"      Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997; 24:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/177\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/178\">",
"      Schellong SM, Schwarz T, Kropp J, et al. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb Haemost 1999; 82 Suppl 1:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/179\">",
"      Partsch H, Bl&auml;ttler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000; 32:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/180\">",
"      Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost 2001; 85:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/181\">",
"      Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa 2001; 30:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/182\">",
"      Aldrich D, Hunt DP. When can the patient with deep venous thrombosis begin to ambulate? Phys Ther 2004; 84:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/183\">",
"      Anderson CM, Overend TJ, Godwin J, et al. Ambulation after deep vein thrombosis: a systematic review. Physiother Can 2009; 61:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/184\">",
"      Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007; 146:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/185\">",
"      Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/186\">",
"      De Martino RR, Wallaert JB, Rossi AP, et al. A meta-analysis of anticoagulation for calf deep venous thrombosis. J Vasc Surg 2012; 56:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/187\">",
"      Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/188\">",
"      Palareti G, Schellong S. Isolated distal deep vein thrombosis: what we know and what we are doing. J Thromb Haemost 2012; 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/189\">",
"      Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/190\">",
"      Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107:I22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/191\">",
"      Masuda EM, Kistner RL. The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation. Dis Mon 2010; 56:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/192\">",
"      Righini M, Paris S, Le Gal G, et al. Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 2006; 95:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/193\">",
"      Schwarz T, Schmidt B, Beyer J, Schellong SM. Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis 2001; 12:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/194\">",
"      Macdonald PS, Kahn SR, Miller N, Obrand D. Short-term natural history of isolated gastrocnemius and soleal vein thrombosis. J Vasc Surg 2003; 37:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/195\">",
"      Gillet JL, Perrin MR, Allaert FA. Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. J Vasc Surg 2007; 46:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/196\">",
"      Lautz TB, Abbas F, Walsh SJ, et al. Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation? Ann Surg 2010; 251:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/197\">",
"      Schwarz T, Buschmann L, Beyer J, et al. Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg 2010; 52:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/198\">",
"      Sales CM, Haq F, Bustami R, Sun F. Management of isolated soleal and gastrocnemius vein thrombosis. J Vasc Surg 2010; 52:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/199\">",
"      Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/200\">",
"      Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 2007; 5:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/4/43082/abstract/201\">",
"      Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41:1633.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1362 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43082=[""].join("\n");
var outline_f42_4_43082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H412636\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Ancillary information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL OBJECTIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevention of further thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention of post-thrombotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Testing for thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      UNFRACTIONATED HEPARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Administration and adequacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LOW MOLECULAR WEIGHT HEPARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outpatient use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Long-term use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18424716\">",
"      FONDAPARINUX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THROMBOLYTIC THERAPY AND THROMBECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Phlegmasia cerulea dolens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INFERIOR VENA CAVA FILTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dose and therapeutic range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7479951\">",
"      OTHER ORALLY-ACTIVE ANTICOAGULANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dabigatran and rivaroxaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7480111\">",
"      Apixaban",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LENGTH OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Idiopathic VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11754089\">",
"      Other guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11754097\">",
"      - 2012 ACCP Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11754105\">",
"      Risk of VTE recurrence after discontinuation of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11754120\">",
"      Risk of major bleeding if anticoagulation is continued",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11754143\">",
"      - Guidance from the ISTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Issues to consider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      RECURRENT VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23454373\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9635933\">",
"      Provoked versus idiopathic events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Length of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11015892\">",
"      - Use of aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26119476\">",
"      Site of initial involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Estimation of individual risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - D-dimer levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Serial imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Thrombin generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Increased risk in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Risk in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15994522\">",
"      General medical management and ambulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15994263\">",
"      ISOLATED CALF VEIN (DISTAL, BELOW THE KNEE) THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Initial anticoagulation regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      VTE and a reversible or time-limited risk factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      First episode of idiopathic VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Recurrent VTE and antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Distal (calf vein) thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7994132\">",
"      Contraindication to anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Anticoagulation failure and massive iliofemoral thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1362|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27534\" title=\"figure 1\">",
"      Warfarin and clotting proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/18/43296\" title=\"figure 2\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1362|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/6/1132\" title=\"table 1\">",
"      Causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/22/44396\" title=\"table 2\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/40/44683\" title=\"table 3\">",
"      Heparin protocol I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/6/21612\" title=\"table 4\">",
"      Heparin protocol II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/28/42444\" title=\"table 5\">",
"      Weight based heparin nomogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/35/16955\" title=\"table 6\">",
"      Outpatient care for VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/21/3420\" title=\"table 7\">",
"      Continuation or discontinuation of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/54/25451\" title=\"table 8\">",
"      Lower extremity vein list",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_4_43083="Revised cardiac risk index";
var content_f42_4_43083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised Goldman cardiac risk index (RCRI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Six independent predictors of major cardiac complications",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-risk type of surgery (examples include vascular surgery and any open intraperitoneal or intrathoracic procedures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of ischemic heart disease (history of MI or a positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrate therapy, or ECG with pathological Q waves; do not count prior coronary revascularization procedure unless one of the other criteria for ischemic heart disease is present)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of HF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of cerebrovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus requiring treatment with insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoperative serum creatinine &gt;2.0 mg/dL (177 &micro;mol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rate of cardiac death, nonfatal myocardial infarction, and nonfatal cardiac arrest according to the number of predictors",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No risk factors - 0.4 percent (95% CI: 0.1-0.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One risk factor - 1.0 percent (95% CI: 0.5-1.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two risk factors - 2.4 percent (95% CI: 1.3-3.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Three or more risk factors - 5.4 percent (95% CI: 2.8-7.9)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        From: Lee TH, Marcantonio ER, Mangione CM, et al. Circulation 1999; 100:1043.",
"       </li>",
"       <li>",
"        From: Devereaux PJ, Goldman L, Cook DJ, et al. CMAJ 2005; 173:627.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43083=[""].join("\n");
var outline_f42_4_43083=null;
var title_f42_4_43084="Visual analog pain scale";
var content_f42_4_43084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Visual analog pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43084=[""].join("\n");
var outline_f42_4_43084=null;
var title_f42_4_43085="Overdiagnosis in cancer scrn";
var content_f42_4_43085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Mechanism of overdiagnosis in cancer screening",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that nonprogressive, as well as some very slow growing, cancers will never cause clinical harm. When these cancers are found on screening, overdiagnosis has occurred. Overdiagnosis is an extreme form of length-time bias.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally reprinted from Welsh, HG. Should I be tested for cancer? Maybe not and here's why. Berkeley and Los Angeles, California: University of California Press, 2004. Reproduced with permission from: Fletcher, RH, Fletcher, SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. p. 147-167. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43085=[""].join("\n");
var outline_f42_4_43085=null;
var title_f42_4_43086="Clinical syndromes by Vibrio species";
var content_f42_4_43086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Number of",
"    <em>",
"     Vibrio",
"    </em>",
"    illnesses (excluding toxigenic",
"    <em>",
"     V. cholerae",
"    </em>",
"    ) by species, complications, and site of isolation in patients from the United States, 2008",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        <em>",
"         Vibrio",
"        </em>",
"        species",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Complications*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Isolates",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Specimen type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Hospitalized",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Deaths",
"       </td>",
"       <td class=\"subtitle2\">",
"        Stool",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blood",
"       </td>",
"       <td class=\"subtitle2\">",
"        Wound",
"       </td>",
"       <td class=\"subtitle2\">",
"        Other&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        N",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        n/N",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        n/N",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        N",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        n",
"       </td>",
"       <td class=\"subtitle3\">",
"        n",
"       </td>",
"       <td class=\"subtitle3\">",
"        n",
"       </td>",
"       <td class=\"subtitle3\">",
"        n",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"13\">",
"        Single species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. alginolyticus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"       <td class=\"centered\">",
"        23/90",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"       <td class=\"centered\">",
"        1/93",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        64",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. cholerae",
"        </em>",
"        (non-toxigenic)&loz;",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        19/48",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        2/47",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. fluvialis",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        29",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        14/27",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"       <td class=\"centered\">",
"        3/27",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        29",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. hollisae",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1/4",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        1/4",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. metschnikovii",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1/1",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        0/1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. mimicus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        32",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        20/29",
"       </td>",
"       <td class=\"centered\">",
"        69",
"       </td>",
"       <td class=\"centered\">",
"        0/30",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        32",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. parahaemolyticus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        270",
"       </td>",
"       <td class=\"centered\">",
"        45",
"       </td>",
"       <td class=\"centered\">",
"        67/256",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"       <td class=\"centered\">",
"        4/254",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        270",
"       </td>",
"       <td class=\"centered\">",
"        44",
"       </td>",
"       <td class=\"centered\">",
"        211",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        37",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         V. vulnificus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        72/84",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        24/79",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        15",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        55",
"       </td>",
"       <td class=\"centered\">",
"        29",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Species not identified",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        23",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        8/22",
"       </td>",
"       <td class=\"centered\">",
"        36",
"       </td>",
"       <td class=\"centered\">",
"        0/21",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Multiple species&sect;",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2/5",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        0/5",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         599",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         227/556",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         40",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         35/561",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         6",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         616",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         305",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         85",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         155",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         71",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Denominators indicate patients for whom information is known.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      The number of isolates is higher than the total number of patients for two reasons: one patient may yield an isolate of the same",
"      <em>",
"       Vibrio",
"      </em>",
"      species from more than one specimen source (eg, the isolation of the same",
"      <em>",
"       Vibrio",
"      </em>",
"      species from 2 specimen sources in the same person is counted as 2 isolates) and more than one",
"      <em>",
"       Vibrio",
"      </em>",
"      species may be isolated from the same patient and each",
"      <em>",
"       Vibrio",
"      </em>",
"      species is counted as an isolate.",
"      <br>",
"       &Delta; Includes ear, sputum, urine, and other.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Includes non-toxigenic",
"        <em>",
"         V. cholerae",
"        </em>",
"        O1 (2 isolates) and other non-toxigenic",
"        <em>",
"         V. cholerae",
"        </em>",
"        [non-O1 non-O139] (47 isolates).",
"        <br>",
"         &sect; The following were isolated from one patient:",
"         <em>",
"          V. alginolyticus",
"         </em>",
"         and",
"         <em>",
"          V. metschnikovii",
"         </em>",
"         ;",
"         <em>",
"          V. alginolyticus",
"         </em>",
"         and",
"         <em>",
"          V. parahaemolyticus",
"         </em>",
"         ;",
"         <em>",
"          V. mimicus",
"         </em>",
"         and",
"         <em>",
"          V. parahaemolyticus",
"         </em>",
"         ;",
"         <em>",
"          V. parahaemolyticus",
"         </em>",
"         and",
"         <em>",
"          V. vulnificus",
"         </em>",
"         ;",
"         <em>",
"          V. parahaemolyticus",
"         </em>",
"         and",
"         <em>",
"          V. vulnificus",
"         </em>",
"         ;",
"         <em>",
"          V. fluvialis",
"         </em>",
"         and",
"         <em>",
"          V. parahaemolyticus",
"         </em>",
"         .",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Summary of human Vibrio cases reported to CDC, 2008. Available at:",
"     <a href=\"file://www.cdc.gov/nationalsurveillance/PDFs/Jackson_Vibrio_CSTE2008_FINAL.pdf\">",
"      file://www.cdc.gov/nationalsurveillance/PDFs/Jackson_Vibrio_CSTE2008_FINAL.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43086=[""].join("\n");
var outline_f42_4_43086=null;
var title_f42_4_43087="Balloon brachytherapy";
var content_f42_4_43087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Balloon brachytherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For intracavitary brachytherapy a radiation delivery device is placed into the partial mastectomy site either at the time of lumpectomy or several days later. High dose radioactive seeds are inserted into the device for a short period of time twice a day for five days. When treatment is completed, the device is removed. Single lumen and multi-lumen balloon catheter and non-balloon devices have all been used successfully.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_4_43087=[""].join("\n");
var outline_f42_4_43087=null;
       